

**PHARMACEUTICAL LAW & INDUSTRY
REPORT & REG; INDEX-SUMMARY**

— Vol. 8, Nos. 1-50 pp. 1-1650
— Jan. 1 - Dec. 31, 2010

NOTE ON ALPHABETIZATION: *This subject index is arranged alphabetically word-by-word. For example, the heading NEW YORK precedes the heading NEWSPAPERS.*

A

ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)

Aplenzin ER, challenge to generic ANDA (D. Del.), 232
Clobetasol propionate emulsion foam, 966
Concerta generic challenge (D. Del.), 1504
Diastat, 1095
Hepsera, 1122
Lovenox raw material released by FDA, 1459
PhosLo GelCaps generic challenge (D. Mass.), 1145
Protonix generic blocked (D.N.J.), 1105; ANDA accepted, 1355
Vytorin generic ANDA (D.N.J.), 7
Welchol generic challenge (D. Del.), 1504
Xyzal ANDA stayed (E.D.N.C.), 1617

ABILIFY

Schizophrenia drug patent enforceable (D.N.J.), 1458

ACCOLATE

Zafirlukast generic, no infringement (D.N.J.), 1497

ACCUTANE

Acne drug and depression, exclusion of causation evidence (N.J. Super. Ct.), 184
Approval of NDA withdrawal, 1524
Bowel disease damages award (N.J. Super. Ct.), 238

ACETADOTE

Applications, 1121; new indications, 1633

ACTEMRA

Arthritis drug approved, 73

ACTHAR

Infantile spasm drug application, 25; FDA panel report, 660; action date extension, 795; more time, 1195

ACTIMMUNE

Marketing, putative class action (N.D. Cal.), 1182
Off-label use, proof of damages (N.D. Cal.), 1462;
DOJ memo, 1616

ACTOPLUS

Diabetes generic settlement (S.D.N.Y.), 644

ACTOS

Diabetes drug and bladder cancer risk, 1233
Generics
—Dr. Reddy's generic challenge (S.D.N.Y.), 717
—Ranbaxy generic settlement (S.D.N.Y.), 353
—Watson generic settlement (S.D.N.Y.), 353

ACUROX

Pain drug, FDA panel rejects, 566

ADVERSE EVENTS *See also SAFETY*

Bar codes and drug errors, 691
Benicar and cardiovascular events, 786
First quarter reports, 686
Genetic basis for events, 254
Matrixx Initiatives non-reporting (U.S., brief filed), 1143; (brief filed), 1470
Pfizer non-reporting, FDA warning, 790

ADVERTISING

Altanax misleading brochure, 599

Aricept, TV commercials cited by FDA, 253
Clinical efficacy, labels and ads, 1558
Colchicine false advertising suit (D.N.J.), 199
Comments on direct-to-consumer ads sought by FDA, 1151
Coupons and DTC ads, FDA seeks comments, 1226
Derma-Smooth misleading website, 1593
Expanded direct-to-consumer ads and drug spending, 691
Gelnique restroom stall ads, 1593
Gleevec misleading website, 599
Italy, OTC ads, 1236
Luvax patient brochure, FDA warning letter, 962
Patient brochures, videos, waiting room sign, FDA warns firms, 166
Photofin website, FDA warning, 1034
Promotional e-mails and webpages, violation letters, 528
Protonix generic, false advertising suit dismissal (E.D. Mich.), 313
RE Methylphen Lanham Act suit (D. Md.), 1081
Remicade direct advertising, no learned intermediary (Tex. App.), 317
Reorganization plan for FDA, 243
Reporting misleading ads, 629
Risk information and direct-to-consumer ads, 864
Seroquel, FDA says materials misleading, 1062
Side effects disclosure, proposed FDA rule, 424
Sleep drug TV ads, FDA violation letters, 791
Social media
—Drug promotion, 819
—FDA policies, 866
Tasigna website, FDA letter, 1061
Va. consumer protection law and drug (W.Va.), 1619
Zyflo CR ads, FDA letter, 899

AFREZZA

Inhalation powder application, 73; no approval, 368;
more time needed, 1636

AIDS AND HIV

African access to drugs, 1527
Colcrys dosing, 632
Diluted drugs (C.D. Cal.), 240
Efavirenz approval, 25
Effectiveness evaluation methods (U.S., rev grant), 1394
Egrifta application, 728; approval, 1474
Fuzeon infringement settlement (E.D.N.C.), 1246
HHS FY2011 budget, 1109
Invirase and heart risk, 1376
J&J overcharging suit (C.D. Cal.), 1621
Nelson seeks drug funding, 1109
Norvir, 219
Pricing suit (C.D. Cal.), 1502
Reyataz
—Generic approval, 1290
—Group facilities, maker barred, 1032
Strides Acrolab product, 44
Sustiva, 218
Videx
—Approval, 531
—Liver disorder, 171
Viread, 173

ALDARA

Skin cream generic infringement settlement (D.N.J.), 516
Topical cream, generic challenge (D.D.C.), 945

ALIMATA

Chemotherapy patent upheld (D. Del.), 1499

ALLEGRA

Antihistamine, generic blocked temporarily (D.N.J.), 744; barred, 773

ALLERGAN

Dry eye treatment patent settlement (E.D. Tex.), 747

ALTABAX

Skin infection treatment, misleading brochure, 599

AMPHETAMINE SULFATE

Withdrawn from sale, 1475

ANDROGEL

Testosterone replacement drug reverse payments, dismissal of FTC suit (N.D. Ga.), 229

ANEMIA DRUGS

Procrit, qui tam suit partial dismissal (U.S., rev sought), 37; Solicitor Gen. input sought, 231; (rev den), 810
Safety, FDA meeting, 70; approval of risk management program, 209

ANGIOMAX

Anticoagulant, PTO refusal to extend patent term (E.D. Va.), 154; vacated, 350; extension ordered, 713; filing timely, 1050; no appeal, 1320
Infringement claim (D. Del.), 1144
Interim patent extension granted, 395

ANTIBIOTICS

Generics
—Merrem I.V., 827
—Norfloxacin, Canadian generic delay (Fed. Ct.), 502
—Vision loss (M.D. Ga.), 355
Levaquin. *See* LEVAQUIN
Noninferiority trials, FDA guidance, 1516
Patents
—Cefaclor infringement claim (Fed. Ct. App.), 1327
—Licensing, 1529
—Omnicef, no infringement (U.S., rev den), 59
TOBI false claims settlement, 586
Trovan. *See* TROVAN

ANTIDEPRESSANTS

Aplenzin ER, challenge to generic ANDA (D. Del.), 232
CPI-300, 219
Effexor. *See* EFFEXOR
Oleptro, 1064
Paxil. *See* PAXIL
Process patent invalid for obviousness (S.D.N.Y.), 809
Wellbutrin. *See* WELLBUTRIN

ANTITRUST

Cancer drugs indirect purchaser suit (D.N.J.), 782
Cipro. *See* CIPRO
Citalopram maker under investigation by EU, 75
Community CarePartners discount program, 896
CVS Caremark merger, antitrust issues, 1472
Direct purchasers sham litigation (N.D. Ga.), 1211
Ethypharm suit against Abbott (D. Del.), 1506
Flonase "brand maturation" (E.D. Pa.), 1464
Generic drugs
—AndroGel
—Overcharging, Supervalu suit (N.D. Ga.), 486
—Reverse payments, dismissal of FTC suit (N.D. Ga.), 229
—Delays due to settlements, action sought, 69
—Flonase "sham" citizen petition allegations (E.D. Pa.), 153
—Mirapex generic dispute (W.D. Pa.), 413
—Pay-for-delay, Senate hearing, 785; House hearing, 989; savings cited, 996; revived Senate efforts, 1024; savings questioned, 1088
—Provigil, subpoena upheld (D.D.C.), 1080
—Toprol maker accused of blocking generics (D. Del.), 515
—TriCor settlement (D. Del.), 59
Inflated pricing, pass-on defense (Cal.), 914; effect of ruling, 958; trial ordered (Cal. Ct. App.), 1183
Joint drug supplier quality and safety audit, 1225
K-Dur purchasers settlement challenge (D.N.J.), 411; appeal, 519
Latanoprost Italian antitrust probe, 1479
Lovenox interlocutory appeal (D.N.J.), 1213

ANTITRUST —Contd.Mergers and acquisitions. *See* MERGERS AND**ACQUISITIONS**

Mexico, firms fined, 295; appeal denied, 869

MiraLax direct purchasers' suit (D. Del.), 678

Monopolies

—Patent ductus arteriosus drugs (D. Minn.), 1176

—Secondary wholesaler claim (2nd Cir.), 852

Norvir predatory pricing (N.D. Cal.), 781

Prandin anticompetitive conduct suit (D. Minn.), 1580

Provigil

—Reverse payments (N.D. Ohio), 748

—Settlements challenge (E.D. Pa.), 412

Reverse payments

—AndroGel, dismissal of FTC suit (N.D. Ga.), 229

—Circuit split, 1299

—Provigil (N.D. Ohio), 748

—Settlements, BNA Insights, 732

Subpoena proper (D.D.C.), 979

Temodar, illegal patent extension allegations (D.

Del.), 316

Unenforceable patents, direct buyer plaintiffs standing

(U.S., rev den), 852

Wellbutrin

—Direct purchaser rep dismissal (E.D. Pa.), 984

—Indirect purchaser suit (E.D. Pa.), 1215; end-payers,

no certification, 1305

—Sham patent litigation alleged (E.D. Pa.), 1179;

reconsideration denied, 1431

ANX-530

Cancer drug application, 45; filing refusal, 332; new name, 370

ANZEMET

Cancer drug heart risk, 1632

APF530

Nausea drug approval denied, 398

APLENZIN ER

Antidepressant, challenge to generic ANDA (D. Del.), 232

APPLICATIONS

Acetadote, 1121; new indications, 1633

Acthar, 25; FDA panel report, 660; action date extension, 795; more time, 1195

Acurox, FDA panel rejection, 566; NDA, 1636

Afrezza, 73; no approval, 368; more time needed, 1636

ANX-530, 45; filing refusal, 332; new name, 370

APF530 rejection, 398

ARC-4558, 1194

Aricept patch, 1234

Avastin and breast cancer, 961; removing indication from label, 1590

Avodart, new indications, 1561

Axanum response letter, 729

AZ-004, 218; more data sought, 1322

Benlysta, 759; priority review, 1122; extended review, 1564

Biologics

—Erwinase, 1443

—Fabry disease treatment, 291

—Filbrin Pad, 1529

—Kidney transplants, 291

—Krystexxa for gout, 369; approval, 1193; available, 1528

—Neuroval biologics license, 170

—Prenar 13, 44

—Privigen, 531

—Simponi, 1260; new indication, 1476

—T-DM1, 932; no fast track, 1162

—Zalbin BLA, 794

Brilinta, 1194; 1633

Bromfenac ophthalmic solution, 25

Bydureon NDA, 566; action date, 634

Byetta, FDA response, 368; more data sought, 1353

Capaxone formulation, 1633

Ceftaroline, FDA panel recommendation, 1157

Cephalon, 25

Certriad, 433

Chemosaturation system, 1636

Cladribine tablets, 1528

CM-AT, 256

Contrave, 829; FDA panel report, 1562

CPI-300, 219

Cymbalta expanded indications, 1118

Cysteamine eye drops, 662

Daxas, FDA panel vote, 500; FDA questions, 1194

DM-1756, 759

Dyloject, 172

Esbriet cleared by FDA panel, 332; no action, 603

Exalgo, 218

Exelbine, 568

Exparel, 1594

Ezogabrine, 1564

Fidaxomicin, 1528

Flutiform, 868

Fortesta, 902

Generic drugs

—Aldara generic challenge (D.D.C.), 945

—Effxor XR, 634; approved, 899

—Protonix generic blocked (D.N.J.), 1105; ANDA accepted, 1355

—Trandate, 219

—Withdrawals not due to safety, 1060

Giazo, 603

Gilenia priority review, 252; cleared by FDA panel, 332

Hexvix, FDA panel approval, 22; decision expected, 74

Horizant denial, 253; FDA questions, 1443

HSDD drug, FDA panel rejects, 825

Illuvien, 1634

Investigational products. *See* LEGISLATION, FEDERAL, HR 4732

Ipilimumab, 1097

JZP-6, 257; 1326

KRX-0401, 471

Laviv application, 23

Linjeta, 1415

Lorcaserin, 24; goal review date, 294; more data sought, 1378; new submission, 1632

Luliconazole, 173

Lupron Depot, 370

Lurasidone, 371

Lyrica application, 23

Motavizumab, 45; FDA panel rejects, 757; more data sought, 1162

Myocet, 74

Naproxinod, FDA panel rejection, 658

Neupro, 569

Neuroval, 1290

Nexium response letter, 729

Northera, 1637

Nuvigil, 433; second response letter, 1636

Ofirmev, 218; resubmission, 531

Omapro, 397

Palomid 259 IND, 191

Parallel review by FDA and CMS, 1223; clinical evidence demand, 1286; PhRMA comments, 1629

Pirfenidone priority review, 43

Pixantrone, 293

Pixuvri, 397; appeal, 1561

Potigq, FDA panel vote, 1095

Pradaxa, FDA panel vote, 1232

Prenar 13 application, 44

Prolia, 256

Proscar, new indications, 1561

Provisional application period extension, 462

PSI-7977, 1097

Qnexa, 24; more data sought, 1409; briefing

document, 1591

Remoxy, 1636

Replagal application, 23

Retigabine, 45

RG2833, 662

Snow delays at FDA, 212

Sprycel new indications, 931

Stedesa, 173

Taliglucerase alfa, 568; accepted for review, 931

Tapentadol, 1290

Tarcera expanded use, 22

Tasigna, 256

Tecarfarin development pathway, 44

Telaprevir, 1529

ThermoDox, 1121

Tideglusib, 1195

Vandetanib, 1260

VIAject, 45; NDA, 294

Vilazodone, 401

Vivitrol, 532; priority review, 730

XiDay, 335

Zelrix, 1416

Zenvia, 662

ZSP-6, FDA panel rejection, 1117

APPROVALS *See also* APPLICATIONS

Acutane NDA approval withdrawal, 1524

Acetaminophen IV, 1412

Actemra, 73

Afinitor, 1443

Aricept doses, 1000

Asclera for varicose veins, 432

Axiron, 1525

Bacitracin, 633

Belatacept, 603

Benicar, 218

Benlysta, FDA panel recommends, 1474

Botox for migraines, 1352

Bromday, 1355; exclusivity, 1476

Cayston, 256

Ceftobiprole, no approval, 43

CIP-Tramadol ER, 633

Crestor, broader indications, 190

Cuvposa oral solution approved, 1033

Cymbalta expanded indications approval, 1442

Dacogen regimen, 370

Daytrana, 901

Differin, 401

Dulera, 868

Efavirenz, 25

Egrifta for lipodystrophy in HIV patients, 1474

Ella, 1094

Eloxatin, stay to end (D.D.C.), 1018

Everolimus, 1416

Exalgo, 335

Famvir approval challenge (D.D.C.), 1244

Faslodex, 1195

Fludarabine phosphate injection, 1290

Gamunex-C, 1244

Gardasil for anal cancer prevention, 1634

Generic drugs

—Aceon, 173

—Actigall, 335

—Adalat, 1594

—Adenoscan, 569

—Aldara, 1160

—Ambien, 1354

—Aricept generic cleared, 1522; approved, 1523

—Arimidex for breast cancer, 253; Roxane generic, 932

—Cardizem, 370

—Cozaar

——Actavis, 1325

——Mylan, 1355

—Crestor, 1290

—Cymbalta, 1529

—Cytovene, 827

—Diastat, 1095

—Differin, 901

—Evoclin, 471

—Flomax. *See* FLOMAX

—Hycamtin, 1528

—Hydroxyzine hydrochloride, 829

—Hypertension generics, exclusivity (D.C. Cir.), 451

—Hyzaar. *See* HYZAAR

APPROVALS—Contd.

Generic drugs—Contd.

—Imitrex
 ——Bedford, 1161
 ——Sagent, 1035
 —Kytril
 ——Sagent, 501
 ——Taro, 760
 —Lamisil, 795
 —Lopressor, 531
 —Lorazepam Intensol, 829
 —Lotrel, 219
 —Lovenox approval challenge (D.D.C.), 975; no withdrawal, 1138
 —Lunesta, 401
 —Merrem I.V., 827
 —Mesnex injection, 531
 —Mirapex, 1381
 —Monistat, 760
 —Nabumetone, 966
 —Namenda, 501
 —Neurontin, 760
 —Niravam, 370
 —NuLytely, 471
 —Pepcid, 902
 —Procardia XL, 868
 —Prograf
 ——Mylan, 1234
 ——Watson, 902
 —Reyataz, 1290
 —Rilutek, 1290
 —Sustiva, 218
 —Tofranil-PM
 ——Lupin, 531
 ——Roxane, 532
 —Toprol XL, 532
 —Tussionex, 1326
 —User fees and quicker approvals, 1224; reopened comment period, 1434
 —Valtrex
 ——Other firms, 730
 ——Watson, 692
 —Videx EC, 531
 —Wellbutrin, 501; new strengths, 965
 —Xanax, 828
 —Xyzal, 1524
 —Yasmin, no stay of approval (S.D.N.Y.), 1136
 —Zemuron, 1035
 —Zocor, 828
 —Zyban, 603
 Gilenya for MS, 1233
 GoLytely, 173
 Halavan for breast cancer, 1474
 Herceptin, 1381
 Hizentra, 335
 Industry relationship with FDA, 1526
 Jalyn, 794
 Jevtana for prostate cancer, 825
 Juvederm XC, 172
 Kaletra, 568
 Kapvay, 1290
 Kombiglyze XR, 1443
 Krystexxa for gout, 1193; available, 1528
 Lamictal XR, 173
 Latuda for schizophrenia, 1410
 Lidocaine with dermal filters, 191
 Lifesaving drugs, speedier approvals sought, 792
 Lo Loestrin FE, 1381
 Lumigan, 1161
 Lumizyme, 688
 Midodrine approval withdrawal, 1096
 Mirapex, 256; extended release, 401
 Morphine sulfate ban (D. Wyo.), 980
 Namenda XR, 827
 Natazia, 632
 Nexterone, 1529
 Noninferiority trials, FDA policy, 1154
 Norvir, 219
 NovoSeven RT, 1063
 Nuedexta, 1416

Octaplex, 1528
 Olepro, 191
 Optical imaging agent, 730
 Oravig, 532
 OxyContin, new formulation, 467
 Pancrease, 500
 Pixastrone, 335
 Posting of safety reports by FDA, 784
 Pradaxa, 1354
 Prolia for osteoporosis, 729
 Protopam Chloride pediatric use, 1194
 Provenge, FOIA (6th Cir.), 203; approval, 598
 Removing unapproved drugs from market (D. Wyo.), 1500
 Retrospective analysis of cancer drug approvals, 250
 Rituxan approved, 254
 Safyral, 1637
 Saphris, 1161
 Silenor, 401
 Solodyn, 1161
 Spiriva HandiHaler, 25
 Sprix, 662
 Sprycel for blood cancer, 1411
 Staxyn, 828
 Stedesa, 603
 Strides Acrolab HIV product, 44
 Success rates of top firms, 1191
 TachoSil patch for cardiovascular surgery, 470
 Tarceva, 532
 Tassigna broader indications, 824
 Taxotere, 1064
 Teflaro for bacterial infections, 1411
 Tekamlo, 1162
 Trelstar formulation, 368
 Tribenzor for blood pressure, 998
 Tykerb for breast cancer, 169
 Valcyte, 1063
 Veletri, 1121
 Vimovo, 603
 Vivitrol for opioid dependence, 1231; approved, 1323
 VPRIV, 293
 Vyvance for ADHD, 1476
 Withdrawn approvals
 —Midodrine, 1096
 —Unfiled annual reports, 1193
 Xeomin, 1035
 Xgerva for cancer bone injuries, 1524
 Xiaflex, 170
 Xifaxan for overt hepatic encephalopathy, 430
 Zortress, 569
 Zuplenz, 901
 Zyclara for actinic keratose, 431

ARALAST

Alpha-1-proteinase inhibitor, misleading brochure, 1159

ARANSEP

Anemia drug, false claims suit dismissal (D. Mass.), 581
 Kidney disease risk, 1353
 Off-label use suit dismissal (9th Cir.), 1363

ARAVA

Rheumatoid drug and liver damage, 928

ARGATROBAN

Anticoagulant generic barred (S.D.N.Y.), 810

ARICEPT

Alzheimer's drug, TV commercials cited by FDA, 253
 Generic cleared, 1522; approved, 1523
 Higher dose, 1000
 Patents
 —Challenged (Fed. Cir.), 1300
 —Dismissal of declaratory judgment suit (M.D.N.C.), 1140
 —Infringement (D.N.J.), 887; stay and dismissal, 982

ARZERRA

Antibody product, noninfringement declaration sought (N.D. Cal.), 233
 Leukemia drug infringement claim (S.D. Cal.), 416

ASCLERA

Varicose vein treatment approval, 432

ASP (AVERAGE SALES PRICE) See PRICING**AUSTRALIA**

Vioxx not fit for purpose, 372

AVANDIA

Access restricted, heart attack and stroke risks, 1229
 Clinical trials, suspension request, 658
 Concealment of risk alleged (E.D. Tex.), 1555
 Diabetes drug, diversity jurisdiction (S.D. Ill.), 626
 Joinder upheld, remand (E.D. Mo.), 890
 Most suits settled, 959
 Santa Clara, Cal., suit over warnings (N.D. Cal.), 355
 Utah Medicaid suit (Utah Dist. Ct.), 1466

AVASTIN

Breast cancer indications, 961; removing from label, 1590

AVODART

Prostate cancer drug, new indications, 1561

AWP (AVERAGE WHOLESALE PRICE) See MEDICAID**AXIRON**

Testosterone deficiency drug approval, 1525

AZ-004

Schizophrenia drug application, 218; more data sought, 1322

B**BANKRUPTCY**

Oscient, 749; approval of liquidation plan (Bankr. D. Mass.), 920
 Vaso Active Ch. 11 filing (Bankr. D. Del.), 389
 Vion Ch. 11 filing (Bankr. D. Del.), 39; liquidation plan, 492

BAYCOL

Cholesterol drug marketing class actions
 —Cal., dismissal sought (Cal.), 275
 —Economic injury class action enjoined (8th Cir.), 61; (U.S., rev grant), 1273
 —Ill., dismissal (Ill.), 8
 Muscle damage, exclusion of expert (8th Cir.), 354

BENICAR

Blood pressure drug and adverse events, 786
 Patent not invalid for obviousness, 1175; (U.S., rev sought), 1615

BENLYSTA

Lupus drug, FDA panel recommends, 1474

BEYAZ

Contraceptive combination approved, 1258

BIAXIN XL

Antibiotic patent upheld in Canada, 905

BIOLOGICS

Applications
 —Erwinase, 1443
 —Fabry disease treatment biologic application, 291
 —Filbrin Pad, 1529
 —Kidney transplant biologic, 291
 —Krystexxa for gout, 369; approval, 1193; available, 1528
 —Neutroval biologics license, 170

BIOLOGICS —Contd.

Applications —Contd.

—Pevnar 13, 44

—Privigen, 531

—Simponi, 1260; new indication, 1476

—T-DM1, 932; no fast track, 1162

—Zalbin BLA, 794

Clinical trials, report from FDA, 1434

Closeout letter for Baxter, 432

Follow-on biologics and FDA agenda, 396; CRS report, 561

Health Canada guidelines, 403

Intellectual property process/platform, 1257

Patents

—Filgrastim infringement suit (E.D. Pa.), 1498

—MS drugs patent infringement (D.N.J.), 749

Posting of safety reports by FDA, 784

BIOLOGICS PRICE COMPETITION AND INNOVATION ACT (BPCI)

Implementation issues, BNA Insights, 1597

BONIVA

Bone drug infringement claim (D.N.J.), 1137; summary judgment, 1182

Generic blocked (D.N.J.), 1460

Osteoporosis drug infringement claim (D.N.J.), 1087

BOTOX

Approval for migraines, 1352

Botulism jury award (Okla. Dist. Ct.), 682

Cerebral palsy patient's death, verdict for maker (Cal. Super. Ct.), 322

False claims settlement (N.D. Ga.), 1131

Spacticity treatment, 334

BPCI *See* **BIOLOGICS PRICE COMPETITION AND INNOVATION ACT (BPCI)****BRAZIL**

Diovan patent extension denial, 26

Generic drugs, EU seizures, 664

Gleevec patent decision, 1382

Lipitor patent expiration, 1163

Price control adjustment for drugs, 372

Retaliation for U.S. cotton subsidies, 373

Valeant purchase, 531

Viagra patent expiration, 604

BRILINTA

Heart drug application, 1633

BUDGET, U.S.

Excess returns tax, White House proposal, 248

Specific agencies. *See specific agencies and departments***BYDUREON**

Diabetes drug application, 566; action date, 634

BYETTA

Diabetes drug application, FDA response, 368; more data sought, 1353

C**CADUET**

Cholesterol generic, infringement suit (D. Colo.), 205

CALIFORNIA

Health reform and drug rebates, 656

Labels, larger type sought, 788

Medicaid

—Pricing, Merck settlement, 21

—Reimbursement cuts

—Chain stores suit, no injunction (9th Cir.), 515

—Pharmacists group suit, cuts enjoined (9th Cir.), 319; suits in 4 states, 484

Step-therapy mandates, proposed ban, 956

CANADA

Biologics, Health Canada guidelines, 403

Extraordinary use new drugs, 472

Generic drugs

—Atomoxetine generic challenge (Fed. Ct.), 1477

—Concerta generic cleared (Fed. Ct.), 693

—Confidentiality order, application (Fed. Ct.), 761

—Glaucoma drugs, challenge (Fed. Ct.), 1445

—Norfloxacin generic delay (Fed. Ct.), 502

Imported drugs

—Conspiracy to reimport (M.D. Pa.), 650

—Mont., Canadian drug imports, 362; pilot program with N.D., 525

—Pricing, agency jurisdiction, 533; appeal, 570

Innovative product data protection (Fed. Ct. App.), 1638

Novartis bid for Alcon, 1067

Patents

—Biaxin XL antibiotic patent upheld, 905

—Cefaclor infringement claim (Fed. Ct. App.), 1327

—Concerta patent invalid (Fed. Cir.), 549

—Escitalopram infringement alleged, 1235

—Norvasc patent invalid, 1065

—Process patent (Fed. Ct. App.), 1417

—Rosuvastatin infringement claims (Fed. Ct. App.), 604

—Viagra patent suit (Fed. Ct.), 830; patent upheld (Fed. Ct. App.), 1327

Pregabalin, no declaration of confidentiality, 571; notice of allegation, 906

Safety

—Improvements urged, 1531

—Side effect reporting, 830

Spending on drugs, 571

Teva and Merck merger, 1037

Transfer of profits sought, 402

User fee hike, 796; update, 1477

CANCER

AEZA-108, 634

Alimata patent upheld (D. Del.), 1499

Anemia drug safety, 1377

ANX-530 application, 45; filing refusal, 332; new name, 370

Anzemet heart risk, 1632

AP24534, 294

ARBs and cancer, 952

Arimidex for breast cancer, 253

Avastin and breast cancer, 961; removing indication from label, 1590

Avodart, new indications, 1561

Bundle pay test, 1380

Carfilzomib, 172

Chemosaturation system, 1636

Colo. insurance mandate for drugs, 687

Conn., oral chemo parity, 726

Eloxatin. *See* **ELOXATIN**

ENMD-2076, 218

Erwinase, 1443

Fludarabine phosphate injection, 1290

Gardasil for anal cancer prevention, 1634

Graspa, 173

Halavan approval, 1474

HRT. *See* **HORMONE REPLACEMENT****THERAPY (HRT)**

Hycamtin, 1528

HyperAcute immunotherapy, 219

IMGN901, 335

Ipilimumab, 1097

Jevtana for prostate cancer, 825

KRX-0401 trial, 191; expedited review, 471

Licensing, 760

Lupron Depot application, 370

Mersana-Teva collaboration, 501

Minn., oral chemo parity, 657

Mylotarg withdrawal, 824

Omapro application, 397

Pixuvri application, 397; appeal, 1561

Proscar, new indications, 1561

Retrospective analysis of cancer drug approvals, 250

Rituxan

—Approved, 254

—Off-label use (E.D. Pa.), 778

Sprycel approval, 1411

T-DM1, 932; no fast track, 1162

Tarceva, 532

Tasigna website, FDA letter, 1061

Taxotere. *See* **TAXOTERE**

Trelstar formulation approved, 368

Tykerb, approval for breast cancer, 169

Vandetanib, 1260; additional doses, 1562

Vesanoid withdrawal, 1191

Vytorin cancer link, 21

Xgerva approval, 1524

CAPAXONE

MS drug formulation, 1633

CARBAGLU

Hyperammonemia drug approved, 398

CARBATROL

Anti-seizure drug, generic patent dispute (D.N.J.), 386

CARDIZEM

Blood pressure drug generic approval, 370

CEFACLOR

Antibiotic infringement claim (Fed. Ct. App.), 1327

CEFTOBIPROLE

Skin infection treatment, no approval, 43

CENESTIN

Estrogen drug, infringement claim (S.D.N.Y.), 776

CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS)

Administrator nominated, 526; GOP criticism, 861; recess appointment, 895; sworn in, 926;

transparency issues, 1256

Medicaid. *See* **MEDICAID**Medicare. *See* **MEDICARE DRUG COVERAGE****CHINA**

Collaboration urged by FDA chief, 1058

Growth in drug sales, prediction, 369

Indian partnership, 1639

CIALIS

ED drug inventorship (Fed. Cir.), 487

CIPRO

Antibiotic patent suit dismissal (D. Md.), 552

Antitrust

—Pay-for-delay settlement upheld (2nd Cir.), 579;

rehearing sought, 675; amended, 853; en banc

review denied, 1130; (U.S., rev sought), 1579

—Summary judgment for maker (Cal. Ct. App.), 681

Tension injury suit (W.D. La.), 556

CIPROFLOXACIN

Cystic fibrosis drug orphan status, 368

CITALOPRAM

Antidepressant, EU antitrust probe of maker, 75

CLASS ACTIONSBaycol. *See* **BAYCOL**

Digitek and economic suffering (S.D. W.Va.), 158

K-Dur purchasers settlement challenge (D.N.J.), 411; appeal, 519

Marketing, Actimmune putative class action (N.D. Cal.), 1182

Matrixx Initiatives securities fraud (U.S., rev grant), 856

Prandin purchaser suit (E.D. Mich.), 715

Schering-Plough stock drop class certification vacated (3rd Cir.), 14; no dismissal (D.N.J.), 891

Trasylol suits remanded (7th Cir.), 888

CLASS ACTIONS—Contd.

Vioxx purchasers suit, no class certification (Cal. Ct. App.), 13; denial upheld (Cal.), 457
Zyprexa overpayments class decertified (2nd Cir.), 1217

CLEVIPREX

Blood pressure drug recall, 24

CLINICAL TRIALS

A-002, 219
Adaptive clinical trial designs, FDA draft guidance, 285
Alzheimer's public database, 793
Antibiotics noninferiority trials, FDA guidance, 1516
Antimicrobial skin infection drugs, draft FDA guidance, 1151; guidance issued, 1516
Asimadoline, 471
Avandia trial, suspension request, 658
Biologic trials, report from FDA, 1434
Carfilzomib, 172
Cost control, 602
Falsification of study data, FDA proposed rule, 247
Foreign studies, HHS IG reports, 862
HyperAcute immunotherapy, 219
KRX-0401, 191
Noninferiority clinical trials, 289; FDA policy, 1154
Postmarket report from FDA, 1434
Safety data, FDA final rule, 1251
Suicide risk, draft FDA guidance, 1151
Trovan trial injuries (U.S., brief filed), 719; (rev den), 852; limited discovery (S.D.N.Y.), 1345
Univ. of Rochester pain drug initiative, 1413
Vascugel, 172

CMS *See* CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS)**COLCRYS**

HIV drug dosing, 632

COLLEGES AND UNIVERSITIES

Harvard conflicts of interest policy, 998
Temple controlled substances plan, 1414
Univ. of Rochester pain drug initiative, 1413
Vanderbilt, Cialis inventorship (Fed. Cir.), 487
Washington Univ. and Pfizer collaboration, 661

COLOCHICINE

Gout drug, unapproved manufacture, 1282

COLORADO

Cancer drug insurance mandate, 687
Medicaid OTC drug coverage, 687
Prescription Drug Monitoring Program, 1374
Unused drugs donations, 498

COMBIGAN

Eye drug copy challenge (E.D. Tex.), 1142
Glaucoma drug, challenge to generic (E.D. Tex.), 35

COMBINATION DRUGS

Beyaz approved, 1258
Good manufacturing practices, FDA proposed rule, 186
Guidance, FDA draft, 1586
Industry practices, FDA proposed rule, 168
Tribenzor approval, 998

COMPARATIVE EFFECTIVENESS

Academic detailing, 524
Challenges outlined, 601
Comments from stakeholders, 1089
Database from patient group, 1525
Federal board members, 1253; balancing views, 1287
FY2010 HHS budget, 187
Guidelines from WellPoint, 689
Key issues remaining, 965
Newly covered Medicare services, 1287
NIH research grants, 359

Nonpharmacological interventions versus medications, *JAMA*, 333
Patient participation, 997
Relevancy focus of stakeholders and experts, 757
Tufts comparison of U.S. and Australia, 929
Useful roles versus adverse effects, 433

CONCERTA

ADHD drug patent invalid (Fed. Cir.), 549
Generic
—ANDA challenge (D. Del.), 1504
—Authorized generic, 1409
—Canada, generic cleared (Fed. Ct.), 693

CONFERENCES AND MEETINGS

American Bar Ass'n, Emerging Issues in Healthcare Law, 259
American Conf. Institute, Maximizing Patent Life Cycles, 1299
Annual Pharmaceutical Regulatory and Compliance Conf., 1347
BIO 2010, 601; 630
Center for Business Intelligence
—4th Annual Forum on Tracking State Laws and Aggregate Spend, 1092
—6th Annual Medical Device and Diagnostic Compliance Congress, 787
Counterfeit Drug Interchange Conf., 1316
FDA/CMS Summit for BioPharma Executives, 1585; 1588
Food and Drug Law Institute, 558
—Emerging Realities in REMS Planning and Execution, 209
4th Summit on Biosimilars and Follow-on Biologics, 396
GPhA/FDA Fall Technical Conf., 1351
Health Care Compliance Ass'n, Physician Practice Compliance Conf., 1351
N.Y. State Bar Ass'n Food, Drug, and Cosmetics Law Section, 163; 169
Risky Business: New Compliance Challenges for FDA-Regulated Industry, 695
Sixth Annual Personalized Medicine Coalition, 284

CONFLICTS OF INTEREST

Attitudes toward industry ties, 826
BNA webinar, 931
Decline in MD-industry ties, 1440
Development of drugs affected, 1377
Disclosure
—Aggregate spend disclosure, BNA Insights, 666
—Federal requirements, 1092
—Pfizer payment disclosure, 468
—Streamlining disclosure, FDA action sought, 1473
—Support studied, 563
FDA, CRS report, 361
Ghostwriting, Senate panel report, 860
Gift reporting, effect of federal law, 787
Harvard policy, 998
Mass. gift disclosure report, 1521
Medical society ethics code, 567
Prescribing decisions, industry influence, 1118
Reputation and litigation risks outlined, 331
Teaching hospitals, guide issued, 900
Vt. free sample reporting, 726

CONNECTICUT

Discounts, state review of Rite Aid, 1114
McKesson pricing settlement (D. Mass.), 1340
Oral chemo parity, 726

CONTRACEPTIVES

Beyaz approved, 1258
Ella approved, 1094; available, 1528
Gianvi. *See* GIANVI
HSDD drug, FDA panel rejects, 825
Lo Loestrin FE, 1381
Natazia, 632
Ortho-Evra patch labeling (N.D. Ohio), 160
Safyral, 1637

Seasonale license, 623
Seasonique generic infringement claim (D. Nev.), 454
Yasmin. *See* YASMIN
Yaz. *See* YAZ

CONTRAVE

Diet drug development, 1160
Obesity drug application, 829; FDA panel report, 1562

COPAXONE

MS drug infringement claim (S.D.N.Y.), 1212

COST CONTAINMENT

Trends in prescription drug spending, 190; health plan forecasts, 1289

COUMADIN

Clotting drug recall, 929

COUNTERFEIT DRUGS

Developing countries, safety concerns, 731
Foreign drug problems, 595
GPhA joins safe drug partnership, 1194
Seizures up, 664
Tamiflu fakes sold on web, 820
Zyprexa counterfeiting conviction vacated (5th Cir.), 320

COZAAR

Exclusivity
—Apotex, injunction denied (D.C. Cir.), 885; (U.S., rev sought), 1301
—Teva, exclusivity upheld (D.D.C.), 349; FDA supports, 414
Generic
—Actavis, 1325
—Mylan, 1355
Hypertension drug generic approval, 451

CRESTOR

Cholesterol drug, approval of broader indications, 190
Generic, 1290
Patents
—Method-of-use patents (D. Del.), 1610
—No infringement (E.D. Pa.), 1461
—Upheld (D. Del.), 919
—Validity affirmed (D. Del.), 883

CRIMINAL PROSECUTION

Bristol-Myers, ex-exec alleged financial fraud (3rd Cir.), 491
Diluted AIDS drugs (C.D. Cal.), 240
Execs of drug and device makers, prosecutions predicted, 1329; focus on individual liability, BNA Insights, 1480
Guidelines for sentencing, 593
Hedge fund insider trading
—French physician (S.D.N.Y.), 1401
—Pharma exec (E.D. Pa.), 1148
Human growth hormone unapproved use (D.R.I.), 1311
Increased enforcement activity against industry, 1640
Medicare billing fraud, sentencing (S.D. Fla.), 1108
Misbranding
—Lyme disease treatment (D. Kan.), 1222
—Plastic surgeons (N.D.N.Y.), 240
Reimported drugs conspiracy (M.D. Pa.), 650
Wire fraud, InterMume ex-CEO (N.D. Cal.), 1019
Zyprexa counterfeiting conviction vacated (5th Cir.), 320

CUBICIN

Antibacterial drug and pneumonia, 1030
Generic challenge, 1561

CUVPOSA

Drooling drug approval, 1033

CYMBALTA

Pain drug, expanded indications, 1118; approved, 1442
 Suicide warning claim (D.S.D.), 1310; summary judgment for maker, 1364

D**DACOGEN**

Myelodysplastic disease drug regimen, 370

DARVOCET

Pain drug and heart attack (E.D. La.), 1624

DAXAS

COPD, FDA panel vote, 500; FDA questions, 1194

DELAWARE

Controlled substances monitoring program, 994

DEPAKOTE

Marketing probe, e-mails sought (W.D. Va.), 518

DERMA-SMOOTH

Topical oil misleading website, 1593

DETROL

Overactive bladder drug, nonobviousness (D.N.J.), 156; patent upheld (D.N.J.), 230

DIASTAT

Anticonvulsant ANDA, 1095

DIET DRUGS *See* WEIGHT LOSS PRODUCTS AND PROGRAMS**DIGITEK**

Economic suffering, class action (S.D. W.Va.), 158; no certification, 816
 Heart drug blamed for death (S.D. Ga.), 1221

DIOVAN

Blood pressure drug, patent extension denial in Brazil, 26

DISCOUNTS

Children's hospitals. *See* LEGISLATION, FEDERAL, HR 4994

Conn. review of Rite Aid, 1114
 Fla. discount card available, 465
 Medicare. *See* MEDICARE DRUG COVERAGE 340B expanded enrollment, 1027

DISTRICT OF COLUMBIA

PBM law preempted (D.C. Cir.), 913

DURAGESIC

Pain patch maker's communications to MDs (W.Va.), 1501
 Wrongful death claim (Tex. App.), 457

E**E-HEALTH**

Collaboration by pharmacy groups, 1258
 E-prescriptions. *See* E-PRESCRIPTIONS
 Electronic health records
 —CMS rules, 1436
 —Incentives, BNA webinar, 1000

E-PRESCRIPTIONS

Controlled substances, DEA rule, 427; interim final rule, 597; concerns raised, 721
 Financial penalties, 1152
 Meaningful use incentives, 862
 Narcotics, Medicare limits, 1371
 Reporting requirements, 1587
 Trends
 —Doubled prescriptions reported, 466
 —Mass. leads states, 1259

—Physician use studied, 999
 W.Va. Medicaid initiative, 1350

EFFEXOR

Antidepressant and suicide, learned intermediary (W.D. Pa.), 277
 Generic
 —Intellipharmaceutics application, 634
 —Orgenon generic challenge (D.N.J.), 1398
 —Teva generic approved, 899
 Preemption and suicide warning
 —No preemption of claims (E.D. Pa.), 1184
 —Risk warning and preemption (10th Cir.), 316

EGRIFTA

AIDS drug application, 728
 Lipodystrophy in HIV patients, 1474

ELLA

Emergency contraceptive approved, 1094

ELOXATIN

Approval, stay to end (D.D.C.), 1018
 Generic
 —Cancer drug, infringement by generic (D.N.J.), 384; generic sales blocked, 552
 —Chemo treatment, generic settlement, 452
 —Launch of generic, 370

ENABLEX

Overactive bladder drug generic, dismissal (D. Del.), 1397

ENFORCEMENT POLICY

E-rulemaking guidelines, 1517
 Effective compliance programs for firms, Special Report, 695
 Exclusion of CEO from program participation, 1511; preview of things to come, 1559
 Renew scrutiny in 2010, BNA Insights, 299
 Unapproved drugs, FDA warning letters, 365

ENTOCORT

Crohn disease generic, patent settlement (D. Del.), 643

EPOGEN

Anemia drug recall, 1258

ERISA

D.C. PBM law preempted (D.C. Cir.), 913

ESBRIET

Lung disease drug cleared by FDA panel, 332; no action, 603

EUROPEAN UNION (EU)

Adverse effect monitoring, 1261
 Antitrust, Citalopram maker under investigation, 75
 Biosimilars draft guidelines, 1530
 Generic drugs
 —Delaying generics, decline in patent settlements, 903
 —India, generic drug seizures, 664; deal with EU, 1382
 —Monetary incentives, 570
 —Raids launched, 1565
 —Seizures in transit, 664
 IMS Health purchase, EU clearance, 171
 Labeling rules, 1530
 Misleading and incorrect data, 1001
 Novartis bid for Alcon, 1067
 Pay-for-delay probes, 75
 Teva purchase of Ratiopharm, 1066

EVAMIST

Menopause drug, adverse effects on children, 1030

EVISta

Osteoporosis drug, generic challenge (S.D. Ind., D. Nev.), 621
 Patent upheld (Fed. Cir.), 1133

EVOXAC

Dry mouth treatment generic settlement (D. Del.), 1053

EXALGO

Painkiller generic challenge (D.N.J.), 1621

EXPERT WITNESSES

Accutane, exclusion of causation evidence (N.J. Super. Ct.), 184
 Baycol and muscle damage, exclusion of expert (8th Cir.), 354
 Metoclopramide and tardive dyskinesia (S.D. W.Va.), 1554
 Neurontin
 —Epilepsy drug and suicide, widow's suit (M.D. Tenn.), 322; expert testimony, 627; settlement, 682
 —No causation (D. Mass.), 1146
 Phenylpropanolamine and neurological ailments (Iowa), 235
 Premarin breast cancer suits (E.D. Ark., D. Minn.), 1219
 Prempro and breast cancer (D.P.R.), 1556
 Trasylol product liability (S.D. Fla.), 1432

F**FABRAZYME**

Fabry disease patients seek access, 1088
 March-in rights, 1584

FALSE CLAIMS

Aggressive recovery at DOJ, 750
 Amgen kickback claims (D. Mass.), 1275
 Aransep suit dismissal (D. Mass.), 581
 Average wholesale price suit, qui tam relator as original source (D. Mass.), 155
 BNA webinar, 931
 Botox settlement (N.D. Ga.), 1131
 Dey pricing settlement (D. Mass.), 1612
 Documents produced in state probe (S.D. Tex.), 982
 Effect of enforcement, 1026
 FOIA and False Claims Act (U.S., brief filed), 1551
 Forest settlement (D. Mass.), 1177
 Gathering qui tam evidence, 1590
 Genetech suit, grand jury transcripts (E.D. Pa.), 1308
 Kadian settlement (D. Md.), 352
 Lipitor marketing qui tam action (E.D.N.Y.), 208
 Medicaid
 —Defending state suits, BNA Insights, 1533
 —Eon Labs settlement (D. Mass.), 232
 —Intervention denied (Wis. Cir. Ct.), 1622
 —Overcharges. *See* PRICING
 —Pfizer off-label marketing and kickbacks suit dismissal (D. Mass.), 1214; appeal (1st Cir.), 1398
 —Pharmacy owner (D. Mass.), 1187
 —Raplon suit dismissal (3rd Cir.), 182
 —Rebate action dismissal (D. Md.), 1143
 —Woodhaven settlement (D. Md.), 1554
 Medicare
 —Raplon suit dismissal (3rd Cir.), 182
 —Woodhaven settlement (D. Md.), 1554
 Off-label use, Rapamune whistleblower suit (E.D. Pa.), 715; DOJ intervention, 1209
 OxyContin suit dismissal (4th Cir.), 417; (U.S., rev den), 1304
 Procrit, qui tam suit partial dismissal (U.S., rev sought), 37; Solicitor Gen. input sought, 231; (rev den), 810
 Public Citizen study, 1625
 Rebates and brand names (D. Md.), 918
 TOBI settlement, 586
 Unapproved drugs, Schwarz Pharma settlement, 585

FAMVIR

ANDA approval challenge (D.D.C.), 1244
 Herpes drug, infringement settlement (D.N.J.), 207

FDA *See* FOOD AND DRUG ADMINISTRATION (FDA)

FEDERAL EMPLOYEES

FEHBP. *See* FEDERAL EMPLOYEES HEALTH BENEFITS PROGRAM (FEHBP)

FEDERAL EMPLOYEES HEALTH BENEFITS PROGRAM (FEHBP)

CVS generic drug prices, 217
Transparency in pricing. *See* LEGISLATION, FEDERAL, HR 4489

FEDERAL TRADE COMMISSION (FTC)

Commissioners confirmation, 360
Enforcement, FTC-DOJ reviews, 1348
Reverse payments. *See* ANTITRUST

FEHBP *See* FEDERAL EMPLOYEES HEALTH BENEFITS PROGRAM (FEHBP)

FENTANYL

Identity of patch maker at issue (N.D. Ohio), 280
Negligent misrepresentation and breach of warranty claims (N.D. Cal.), 650
Pain drug overdose death punitive damages (D. Utah), 1248
Recall announced, 1379
Transdermal patch implied warranty and fraud claims (M.D. Fla.), 279

FILGRASTIM

Biologic infringement suit (E.D. Pa.), 1498

FLOMAX

Generics
—Boehringer prostate drug generic approval, 292
—Caraco, 1000
—Mylan generic approval, 568
Shipped, 1000

FLONASE

Allergy drug generic, “sham” citizen petition allegations (E.D. Pa.), 153; off-the-record, 921
Asthma drug generic, “brand maturation” (E.D. Pa.), 1464

FLORIDA

Discount card available, 465
Drug pricing website, 822
Medicaid pricing, Merck settlement, 21

FOCALIN

ADHD drug, infringement claims dismissal (D.N.J.), 156

FOOD AND DRUG ADMINISTRATION (FDA)

Additional resources urged, 392
Advancing regulatory science, 1314
Agenda for guidance, 1558; 2011 agenda, 1585
Budget
—FY2011 funding. *See* LEGISLATION, FEDERAL, S 3606
—Senate hearings, 327
—Spending bill signed, 1282
Commissioner
—Rare diseases chief, 289
—Senate panel approves, 19
Conflicts of interest, CRS report, 361
Consumer reps on advisory panel, 1630
Criminal enforcement
—GAO report, 324
—Investigations chief retirement, 1520
Enforcement power. *See* LEGISLATION, FEDERAL, S 3690
FDA-TRACK launch, 1149
FY2011 budget proposal, 164; House panel approval, 894; Senate bill, *see* LEGISLATION, FEDERAL, S 3606
Generic drugs chief transfer, 328
Improving agency, FDA chief counsel speaks, 163
Labels and packaging. *See* LABELS AND PACKAGING

Management planning, GAO report, 427
Marketing and advertising, FDA reorganization plan, 243
Overhaul. *See* LEGISLATION, FEDERAL, HR 4816
Public meeting procedures, 1589
Recall authority. *See* LEGISLATION, FEDERAL, HR 5740
Recruitment and retention at FDA, GAO report, 286
Regulatory science advancement, 392
Safety office, Grassley urges, 558; authority expansion sought, 1316
Science board nominations, 1349
Strategic priorities draft, 1281
Transparency initiative
—Comments sought, 357
—Draft guidance, 523
—Industry concerns, 950
—Proposals issued, 652
—Website launch, 70

FOSAMAX

Causation lacking (S.D.N.Y.), 1509
Defense verdict in jaw osteonecrosis suit (S.D.N.Y.), 624
Femur breaks, FDA review, 358
Jury award for jaw deterioration (S.D.N.Y.), 855; reduced, 1344
Osteoporosis drug and osteonecrosis of the jaw (S.D.N.Y.), 159; suit untimely, 388
Victory for maker in osteonecrosis suit (2nd Cir.), 1466

FRANCE

Generic drugs, efforts to block, 693

FRAUD AND ABUSE

Aggressive enforcement at DOJ, 1347
BNA webinar, 256
Bristol-Myers, ex-exec alleged financial fraud (3rd Cir.), 491
Counterfeit drugs. *See* COUNTERFEIT DRUGS
Effective enforcement by FDA, 1375
Elan promotions settlement, 1578
Exclusions from federal programs, drug execs challenge (D.D.C.), 161; 12-year ban, 1575
False claims. *See* FALSE CLAIMS
Foreign Corrupt Practices Act
—Merck data sought, 1094
—Prosecution trends, 214
—Vigilance by firms, 655
Grassley whistleblower query, 895; anti-fraud funding, 1630
Guidelines for sentencing, 593
Human growth hormone unapproved use (D.R.I.), 1311
Increased prosecution of executives, 1375
Ind. health care fraud enforcement efforts, 1115
Kickbacks
—Amgen kickback claims (D. Mass.), 1275
—Effect of enforcement, 1026
—Foundation's assistance program, 1153
—Kaletra kickback claims (D. Mass.), 943
—Kos settlement (M.D. La.), 1550
—Nonprofit's assistance program, 753
—Pfizer off-label marketing and kickbacks suit dismissal (D. Mass.), 1214
—Uninsured and copayments, 724
Medicaid
—Integrity issues for 2011, 1351
—Miss. AWP misrepresentation suit (Miss.), 517
—Pennsylvania
—Bristol-Myers AWP case (Pa. Commw. Ct.), 1305
—J&J AWP reporting (Pa. Commw. Ct.), 1612
—Qui tam relator as original source (D. Mass.), 155
—S.C. AWP settlements, pharmacies held harmless, 787
—Teva pricing settlement, 960
—Utah AWP suit against firms dismissed (Utah Dist. Ct.), 271

Medicare

—Billing, sentencing (S.D. Fla.), 1108
—Invalid prescriber identifiers, 1227
—J&J suit over Procrit and Remicade (D. Mass.), 1209
Misconduct in research, anesthesiologist, pain drug data fabrication guilty plea (D. Mass.), 280; sentenced, 858
Motives for whistleblowing, 662
N.Y. financial relationships between providers and drug and device makers, 169
Obstruction and false statements in FDA probe (D. Md.), 1427; not guilty plea, 1552
Off-label use. *See* OFF-LABEL USE
Overutilization of drugs, 1371
Pricing. *See* PRICING
Rebate checks targeted, 725
Recoveries
—DOJ for FY2010, 1519
—HHS OIG report, 1586
Seroquel illegal marketing settlement, 563
Theft of drugs and devices, 562
Wire fraud, InterMume ex-CEO (N.D. Cal.), 1019

FUZEON

AIDS drug infringement settlement (E.D.N.C.), 1246

G

GAMMAGARD

Immune globulin IV lots withdrawn, 759

GARDASIL

HPV vaccine approval for anal cancer prevention, 1634

GELNIQUE

Overactive bladder restroom stall ads, 1593

GEMZER

Cancer drug patent valid (S.D. Ind.), 453
Method patent invalid (Fed. Cir.), 1013; rehearing denied, 1393

GENERIC DRUGS

Actos. *See* ACTOS
Allegra, generic blocked (D.N.J.), 744
Analpram, 532
Antibiotics, vision loss and generic (M.D. Ga.), 355
Antitrust
—AndroGel
—Overcharging, Supervalu suit (N.D. Ga.), 486
—Reverse payments, dismissal of FTC suit (N.D. Ga.), 229
—Delays due to settlements, action sought, 69
—Flonase “sham” citizen petition allegations (E.D. Pa.), 153
—Mirapex generic dispute (W.D. Pa.), 413
—Pay-for-delay, Senate hearing, 785; House hearing, 989; savings cited, 996; revived Senate efforts, 1024; savings questioned, 1088
—Provigil, subpoena upheld (D.D.C.), 1080
—Toprol maker accused of blocking generics (D. Del.), 515
—TriCor settlement (D. Del.), 59
Applications
—Aldara generic challenge (D.D.C.), 945
—Effexor XR, 634; approved, 899
—Protonix generic blocked (D.N.J.), 1105; ANDA accepted, 1355
—Trandate, 219
—Withdrawals not due to safety, 1060
Approvals
—Aceon, 173
—Actigall, 335
—Adalat, 1594
—Adenoscan, 569
—Aldara, 1160
—Ambien, 1354
—Ariccept generic cleared, 1522; approved, 1523

GENERIC DRUGS—Contd.

Approvals—Contd.

—Arimidex for breast cancer, 253; Roxane generic, 932
 —Cardizem, 370
 —Cozaar
 — —Actavis, 1325
 — —Mylan, 1355
 —Crestor, 1290
 —Cymbalta, 1529
 —Cytovene, 827
 —Diastat, 1095
 —Differin, 901
 —Evoclin, 471
 —Flomax. *See* FLOMAX
 —Hycamtin, 1528
 —Hydroxyzine hydrochloride, 829
 —Hypertension generics, exclusivity (D.C. Cir.), 451
 —Hyzaar. *See* HYZAAR
 —Imitrex
 — —Bedford, 1161
 — —Sagent, 1035
 —Kytril
 — —Sagent, 501
 — —Taro, 760
 —Lamisil, 795
 —Lopressor, 531
 —Lorazepam Intenol, 829
 —Lotrel, 219
 —Lovenox approval challenge (D.D.C.), 975; no withdrawal, 1138
 —Lunesta, 401
 —Merrem I.V., 827
 —Mesnex injection, 531
 —Mirapex, 1381
 —Monistat, 760
 —Nabumetone, 966
 —Namenda, 501
 —Neurontin, 760
 —Niravam, 370
 —NuLyteLy, 471
 —Pepcid, 902
 —Procardia XL, 868
 —Prograf
 — —Mylan, 1234
 — —Watson, 902
 —Reyataz, 1290
 —Rilutek, 1290
 —Sustiva, 218
 —Tofranil-PM
 — —Lupin, 531
 — —Roxane, 532
 —Toprol XL, 532
 —Tussionex, 1326
 —Valtrex
 — —Other firms, 730
 — —Watson, 692
 —Videx EC, 531
 —Wellbutrin, 501; new strengths, 965
 —Xanax, 828
 —Xyzal, 1524
 —Yasmin, no stay of approval (S.D.N.Y.), 1136
 —Zemuron, 1035
 —Zocor, 828
 —Zyban, 603
 Argatroban generic barred (S.D.N.Y.), 810
 Boniva generic blocked (D.N.J.), 1460
 CEO leaves industry group, 602
 Cipro pay-for-delay settlement upheld (2nd Cir.), 579; en banc review denied, 1130; (U.S., rev sought), 1579
 Concerta. *See* CONCERTA
 Cubicin copy challenge, 1561
 Desoxyx, 569
 Effexor. *See* EFFEXOR
 Eloxatin. *See* ELOXATIN
 European Union (EU)
 —Delaying generics, decline in patent settlements, 903
 —India, generic drug seizures, 664; deal with EU, 1382

—Monetary incentives, 570
 —Raids launched, 1565
 —Seizures in transit, 664
 Evista generic challenge (S.D. Ind., D. Nev.), 621
 Exelon, 902
 Flomax. *See* FLOMAX
 Flonase “brand maturation” (E.D. Pa.), 1464
 Impurities, FDA guidance, 1517
 India, EU seizures, 664; deal with EU, 1382
 International developments
 —Canada
 — —Atomoxetine generic challenge (Fed. Ct.), 1477
 — —Concerta generic cleared (Fed. Ct.), 693
 — —Confidentiality order, application (Fed. Ct.), 761
 — —Glaucoma drugs, challenge (Fed. Ct.), 1445
 — —Norfloxacin generic delay (Fed. Ct.), 502
 —EU. *See* European Union (EU), *this heading*
 —France, efforts to block generics, 693
 Lipitor. *See* LIPITOR
 Lovenox generic announced, 995
 Medicaid
 —Rates, GAO report, 1628
 —Savings and switching, 930; substitutions, 996
 Metaxalone generic blocked (D.N.J.), 641
 Metoclopramide failure to warn claims (U.S., rev sought), 677; (brief filed), 1086; DOJ position (brief filed), 1428; (rev grant), 1577
 Mirapex. *See* MIRAPEX
 Optivar, 901
 Oracea generic blocked, 887
 Patents
 —Accolate generic, no infringement (D.N.J.), 1497
 —ACTOplus settlement (S.D.N.Y.), 644
 —Aldara infringement settlement (D.N.J.), 516
 —Alimata patent upheld (D. Del.), 1499
 —Aplenzin ER, challenge to generic ANDA (D. Del.), 232
 —Atomoxetine generic challenge (Fed. Ct.), 1477
 —Boniva infringement claim (D.N.J.), 1137; summary judgment, 1182
 —Caduet generic, infringement suit (D. Colo.), 205
 —Carbatrol, generic patent dispute (D.N.J.), 386
 —Cipro patent suit dismissal (D. Md.), 552
 —Combigan. *See* COMBIGAN
 —Concerta generic challenge (D. Del.), 1504
 —Delay of market entry, 893
 —Eloxatin. *See* ELOXATIN
 —Enablex suit, dismissal (D. Del.), 1397
 —Entocort settlement (D. Del.), 643
 —Evoxac generic settlement (D. Del.), 1053
 —Exalgo generic challenge (D.N.J.), 1621
 —Exclusivity, FDA determination rule challenge (D.D.C.), 267; BNA Insights, 606; rehearing denied, 644
 —Famvir infringement settlement (D.N.J.), 207
 —Gemzer patent valid (S.D. Ind.), 453
 —Hectoral generic challenge (D. Del.), 682
 —Hyperparathyroidism drugs (N.D. Ill.), 647
 —Integrilin infringement suit (D. Del.), 551
 —Lialda infringement alleged (D. Del.), 947
 —Lovenox copy challenge (D. Mass.), 1550
 —Lucox CR settlement (D. Del.), 1141
 —Lunesta, inequitable conduct claims (D.N.J.), 774; settled, 1054
 —Malarone infringement settlement (D. Del.), 485
 —Meridia, challenge to generic (D. Del.), 36
 —MoviPrep settlement (D.N.J.), 1144
 —Mucinex, generic no infringement (W.D. Mich.), 200; vacated, 1051
 —Namenda. *See* NAMENDA
 —Nexium. *See* NEXIUM
 —Nuvigil. *See* NUVIGIL
 —Oraped ODT infringement claim (D. Del.), 1620
 —Paxil, TRO denied (D.N.J.), 1340; no injunction, 1395
 —Prandin infringement suit dismissal (D.N.J.), 483
 —Prilosec infringement (Fed. Cir.), 5
 —Protonix patent valid (D.N.J.), 584; upheld, 941
 —Pulmicort generic blocked (Fed. Cir.), 1391
 —Renvela, generic challenge (D. Md.), 717

—Restoril patent obvious, 586
 —Seasonique infringement claim (D. Nev.), 454
 —Simcor challenge (D. Del.), 623
 —Solodyn. *See* SOLODYN
 —Stalevo, infringement settlement (D.N.J.), 813
 —Strattera induced infringement claim (D.N.J.), 33; patent invalid, 1079
 —Tarka, no injunction (D.N.J.), 775
 —Treximet, generic challenge (E.D. Tex.), 485
 —Ultracet settlement (D.N.J.), 747
 —Uroxatral generic infringes (D. Del.), 642; patent upheld, 1106
 —Valcyte settlement (D.N.J.), 1142
 —Viagra infringement claim (E.D. Va.), 454
 —Vytorin generic challenge (D.N.J.), 1107
 —Welchol generic challenge (D. Del.), 1504
 —Yasmin. *See* YASMIN
 —Yaz generic challenge (D. Del.), 713
 —Zymar patent invalid (D. Del.), 851
 PhosLo GelCaps generic challenge (D. Mass.), 1145
 Pricing, effect of generics, 757
 Reglan. *See* REGLAN
 REMS, comments on FDA draft guidance, 41
 Revlimid, 1564
 Sandoz and Oriol, 531
 Savings, HHS report, 1626
 Subpoena for CEO (D.D.C.), 1553
 Timoptic-XE, 334
 User fees, planned FDA meeting, 1058; preparing negotiations, 1150; quicker approvals, 1224; reopened comment period, 1434
 Vigamox generic stayed (D. Del.), 1053
 Vytorin. *See* VYTORIN
 Wellbutrin, sham patent litigation alleged (E.D. Pa.), 1179; reconsideration denied, 1431
 Zetia. *See* ZETIA
 Zymaxid, 692

GENETICS AND BIOTECHNOLOGY

Biosimilars

—Biologics Price Competition and Innovations Act, BNA Insights, 698
 —BNA webinar, 1000
 —EU draft guidelines, 1530
 —Health reform implementation, 898
 —Investment in technology, 965
 —Meeting participation, 1560
 —Pathway, FDA efforts, 558; implementation issues, 688; practitioner comments, 865; guidance expected, 1230; hearing planned, 1280; biosimilar challenges, 1312; clinical trials, unique names sought, 1404; implementation challenges, 1514
 —Pfizer and Biocon collaboration, 1352
 —Stakeholders comments, 1403
 —2010 FDA agenda, 630
 —Watson and Itero collaboration, 965
 Tailoring prescriptions to genetics, 758

GIANVI

Contraceptive label corrections (N.D. Ill.), 814
 Patent infringement claim dismissal (D. Del.), 886

GILENYA

MS drug priority review, 252; cleared by FDA panel, 790; approved, 1233

GLEEVEC

Brazilian patent decision, 1382
 Gastrointestinal cancer drug, misleading website, 599

GNRH

Prostate drug and diabetes, 591

GRANTS

Comparative effectiveness, NIH research grants, 359
 Therapeutic discovery project program, 1408

H

HALAVAN

Breast cancer drug approval, 1474

HEALTH AND HUMAN SERVICES

DEPARTMENT (HHS)

Budget

—AIDS and HIV, FY2011 budget, 1109
—FY2010 budget, effectiveness research, 187
CMS. *See* CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS)

FDA. *See* FOOD AND DRUG ADMINISTRATION (FDA)

Open government plan, 460

HEALTH CARE REFORM, FEDERAL

Accounting rules, 1632
Annual drug company fee, 1518
Biosimilars pathway, 688
BNA webinar, 568
Cal. drug rebates, 656
Cost to drug makers, estimate, 430
Delivery system reform proposals, 255
Harkin on quality, 631
Industry effects
—Benefits, 901
—Fees, 1120
Life science firms, effect of reform, 727
Lobbyists, spending up, 216
Markets, effect on, 527
Medicaid rebates and reform, 564; effect of new rules, 1114
Overhaul. *See* LEGISLATION, FEDERAL, HR 3590
Payment advisory board. *See* LEGISLATION, FEDERAL, S 3653
Pricing effects, 1437
Reconciliation bill. *See* LEGISLATION, FEDERAL, HR 4872
Repeal sought, 1406
Timeline from CBO, 1438
Transparency and disclosure, BNA Insights, 503
White House
—Revamped proposal, 241
—Simple majority sought, 287

HEALTH INFORMATION TECHNOLOGY FOR ECONOMIC AND CLINICAL HEALTH ACT (HITECH) ACT

BNA webinar, 931
Privacy rules and drugmakers, BNA Insights, 1038

HEALTH INSURANCE

Cal., step-therapy mandates, proposed ban, 956
Cancer, bundled pay test, 1380
Cost sharing and drug utilization, 1415
New York
—Copay limits, 1284
—Formulary specialty tiers, 755; banned, 1284
Reform. *See* HEALTH CARE REFORM, FEDERAL

HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA)

Privacy, Rite Aid HIPAA settlement, 992

HECTORAL

Kidney drug, generic challenge (D. Del.), 682

HELIXATE FS

Hemophilia drug patent settlement (E.D. Tex.), 273

HEPARIN

Antitrust challenge (D.N.J.), 1083
Blood thinner, less activity, 461
Contamination, report, 596; recall, 1414; FDA criticized, 1436
Design defect and strict liability (D.N.J.), 1556

HEXVIX

Imaging agent, FDA panel approval, 22

HIPAA *See* HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA)

HITECH ACT *See* HEALTH INFORMATION TECHNOLOGY FOR ECONOMIC AND CLINICAL HEALTH ACT (HITECH) ACT

HORIZANT

Restless leg drug application denial, 253; FDA questions, 1443

HORMONE REPLACEMENT THERAPY (HRT)

Knowledge of injury and breast cancer (Pa. Super Ct.), 64
Premarin. *See* PREMARIN
Prempro. *See* PREMPRO
Provera and breast cancer (Pa. Super. Ct.), 64
Punitive damages retrial (U.S. brief filed), 718; (rev den), 816
Time-barred claims (D. Minn.), 1279
Wyeth award upheld (Nev.), 1507

HRT *See* HORMONE REPLACEMENT THERAPY (HRT)

HUMIRA

Arthritis drug infringement damages and interest (E.D. Tex.), 6
Lymphoma suit (N.D. Cal.), 857
NYU infringement suit (E.D. Tex.), 6

HYLENEX

Recombinant recall, 660

HYZAAR

Generic
—Mylan, 501; final approval, 1355
—Teva, 451
Hypertension drug exclusivity upheld (D.D.C.), 349; FDA supports, 414

I

IDAHO

Actavis Medicaid pricing settlement (Idaho Dist. Ct.), 714
Sandoz Medicaid pricing settlement (Idaho Dist. Ct.), 1341

ILLUVIEN

Eye drug application, 1634

INCRELAX

Growth failure treatment promotional materials, 1442

INDIA

Chinese partnership, 1639
Generic drugs
—EU seizures, 664; deal with EU, 1382
—Global brand-building campaign, 1565
Patents on drugs, Analysis & Perspective, 46
Price controls, 1163

INDIANA

Health care fraud enforcement efforts, 1115

INFLUENZA

Emergency drug supplies, FDA guidance, 71; information sought, 1349

INFORMATION NETWORKS AND TECHNOLOGY

Clinical trials, Alzheimer's public database, 793
Pharmacies, database of patient services, 171

INTEGRILIN

Anti-clotting drug infringement suit (D. Del.), 551

INTELLECTUAL PROPERTY

Biologics process/platform, 1257
Patents. *See* PATENTS
Russia, improved protection, 1356
Special 301 list criticized, 964
Trade secrets theft indictment against Bristol-Myers ex-worker (N.D.N.Y.), 183

INTERNATIONAL DEVELOPMENTS

Counterfeit drugs and developing countries, 731
Imported drugs
—Conspiracy to reimpose (M.D. Pa.), 650
—Counterfeit drugs, 595
—Developing countries and generics, 1444
—Mont., Canadian drug imports, 362; pilot program with N.D., 525
—Pricing, Canadian agency jurisdiction, 533; appeal, 570
—Safety, Senate hearings, 327
Pan American Health Organization and FDA, 1317
Russia, collaboration with PTO, 796
Tariff elimination, 1228
Trans-Pacific Partnership, 1196
Trends
—Growth of global market, 1320
—Patents, decline in international findings, 221

INTERNET

Amag webpages, FDA scrutiny, 1378
FDA
—FDA-TRACK launch, 1149
—Transparency initiative, website launch, 70
Fla. drug pricing website, 822
Tamiflu fakes sold on web, 820
Tasigna website, FDA letter, 1061

INTUNIV

ADHD starter kit, FDA says misleading, 899

INVIRASE

HIV drug and heart risk, 1376

IOWA

Medicaid AWP suit dismissal (D. Mass.), 1465

IPLEX

Investigational drug, access (N.D.N.Y.), 1399

ITALY

Latanoprost antitrust probe, 1479
OTC ads, 1236

J

JEVTANA

Prostate cancer drug approval, 825

JURISDICTION

Avandia
—Aaron suit diversity jurisdiction (S.D. Ill.), 626
—Douglas suit, no diversity (E.D. Mo.), 890
Crestor method-of-use patents (D. Del.), 1610
Paxil product liability, no change of venue (E.D. Pa.), 11
Trasylol product liability
—4 suits remanded (7th Cir.), 888
—Mass tort, no remand (S.D. Ill.), 12
Wyeth transfer denied (Fed. Cir.), 1615

K

KADIAN

Painkiller false claims settlement (D. Md.), 352

KALETRA

HIV drug off-label use (D. Mass.), 943

KAPIDEX

Heartburn drug name change, 333

KENTUCKY

GSK marketing settlement, 1156

KRYSTEXXA

Gout biologic application, 369; approval, 1193

L

LABELS AND PACKAGING *See also* SAFETY; WARNINGS

Arava and liver damage, 928
Avastin and breast cancer, 1590
Cal., larger type sought, 788
Clinical efficacy, labels and ads, 1558
Colcrys dosing, 632
Diabetes drugs, MDs' group sues FDA (D.D.C.), 916
Draft guidance from FDA, 859; final rules, 1625
EU rules, 1530
Gadolinium-based contrast agents, 1188
Gianvi label corrections (N.D. Ill.), 814
Hypertension indication, FDA proposed guidance, 392
Invirase and heart risk, 1376
LABAs and asthma, 752
Lamisil and skin disease (D.N.J.), 1218
Motrin labeling, preemption of Tex. law (N.D. Tex.), 157
Off-label use. *See* OFF-LABEL USE
Ortho-Evra patch labeling (N.D. Ohio), 160
Osteoporosis drugs updated labels, 1314
Plavix boxed warning, 367
Propylthiouracil boxed warning, 566
Regulatory agenda for FDA, 592
Standardization proposal, 632
Tysabri, 1636
Velcade, 45
Vivitrol, 600
WinRho SDF boxed warning, 371
Workshop at FDA, 494

LAMISIL

Anti-fungal drug and skin disease (D.N.J.), 1218

LATANOPROST

Glaucoma drug, Italian antitrust probe, 1479

LATUDA

Schizophrenia drug approval, 1410

LAVIV

Wrinkle treatment application, 23

LEGISLATION, FEDERAL

HR

—**628**, Patent expertise at district courts, 1628
—**1586**, Increased Medicaid matching funds, 1028
—**3590**, Patient Protection and Affordable Health Act, Democratic reform bill Senate passage, 17; Medicaid reimbursement, 18; pay-for-delay proposal, 42; implementation issues, 390; signed, 425; key provisions, Special Report, 435
—**3962**, Affordable Health Care for America Act, pay-for-delay proposal, 42
—**4213**, American Jobs and Closing Tax Loopholes Act, Rangel, Medicaid matching funds, 684
—**4489**, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act, Lynch, addresses prices, 249; House panel approves, 424
—**4732**, Compassionate Access Act, Watson, would ease access to investigational products, 329
—**4816**, FDA Administration Improvement Act, Hinchey, would overhaul agency, 361
—**4872**, Health Care and Education Reconciliation Act, Medicaid rebates, signed, 423; key provisions, Special Report, 435
—**4899**, Supplemental Appropriations Act, 2010, would bar patent settlements that delay generics market entry, House approval, 893
—**4994**, Medicare and Medicaid Extenders Act, restoring children's hospital drug discounts, 1586

—**5712**, Veterans', Seniors', and Children's Health Technical Corrections Act, Medicare/Medicaid/CHIP technical corrections, 926
—**5732**, Medicare off-label coverage, Kilroy, 955
—**5740**, FDA mandatory recall of adulterated or misbranded drugs, Towns, 953

S

—**2942**, Nanotechnology Safety Act, Prior and Cardin, would establish FDA program, 212
—**3000**, Federal Medical Assistance Percentage increase, Rockefeller, 216
—**3606**, FDA FY2011 funding, 952
—**3653**, Health Care Bureaucrats Elimination Act, would end payment advisory board, 1029
—**3690**, Drug Safety and Accountability Act, Bennet, would increase FDA enforcement power, 1025

LEVAQUIN

Antibiotic and tendon toxicity, no consolidation (D. Minn.), 36; no summary judgment, 1021
Labeling, petitions admissible (D. Minn.), 1505; failure to warn, \$1.7M award, 1582
Patent extension (Fed. Cir.), 617; BNA Insights, 762; rehearing denied, 976

LIALDA

Ulcerative colitis drug infringement alleged (D. Del.), 947

LIPITOR

Brazilian patent expiration, 1163
Cholesterol drug marketing qui tam action (E.D.N.Y.), 208; no DOJ intervention, 1247
Discovery compelled (N.D. Ill.), 1085
Infringement, transfer request denial (Fed. Cir.), 181
Philippines, generic retail sales, 221; reconsideration sought, 258
Recall, 1414; another lot recalled, 1635

LOBBYING

PhRMA chief's departure, 215; new CEO, 928; chairman named, 1563

LORCASERIN

Weight-loss drug application, 24; goal review date, 294; more data sought, 1378; resubmission, 1632

LOUISIANA

Medicaid overcharges (La. Dist. Ct.), 1430
Zyprexa off-label use settlement (E.D.N.Y.), 488

LOVENOX

Generic
—Anticoagulant generic announced, 995
—Blood-thinning drug, generic approval challenge (D.D.C.), 975; no withdrawal, 1138
—Challenged (D. Mass.), 1550
Raw material sought (D.D.C.), 1396; released by FDA, 1459

LUCOX CR

OCD drug generic settlement (D. Del.), 1141

LUMIGAN

Elevated Intraocular pressure drug promotion, 1563

LUMIZYME

Pompe disease drug approval, 688

LUNESTA

Approval of generic, 401
Sleeping pill generic inequitable conduct claims (D.N.J.), 774; settled, 1054

LUVAX

Anxiety drug patient brochure, FDA warning letter, 962

LYRICA

Anxiety disorder drug application, 23

M

MAINE

Prescribing data sales limits (1st Cir.), 1049

MALARONE

Malaria drug generic, infringement settlement (D. Del.), 485

MARINOL

Nausea drug off-label promotion (U.S., rev den), 815

MARKETING

Actimmune putative class action (N.D. Cal.), 1182
Amag webpages, FDA scrutiny, 1378
Aralast misleading brochure, 1159
Aton promotions, violation letters, 499
Baycol. *See* BAYCOL
Biogen promotions, violation letters, 499
Cambia, 759
Caraco and Sun distribution pacts, 1636
Consumer video, violation letter, 565
Depakote probe, e-mails sought (W.D. Va.), 518
Desoxyn generics, 569
Donations to mental health organization, 596
Genentech, FDA violation letter, 600
Gilead promotions, violation letters, 499
Increlax promotional materials, 1442
Intuniv starter kit, FDA says misleading, 899
Johnson & Johnson communications to MDs (W.Va.), 1501
Kalbitor, 172
Ky. GSK marketing settlement, 1156
Lilly overseas marketing probe, 252
Livalo, 828
Lodosyn, 568
Lorcaserin, 902
Lumigan promotion, 1563
Lyrica, 532
Nexium deceptive marketing suit (D. Del.), 645
Oleptro, 1064
Online marketing, FDA actions sought, 1516
Oral colchicine unapproved uses (D.N.J.), 1397
Patient profile, violation letter, 565
Pennsaid, 568
Professional sales aids, violation letter, 565
Qutenza, 471
Rapamune, 633; promotion for unauthorized uses, 784
Reorganization plan for FDA, 243
Reyataz maker barred from AIDS group facilities, 1032
Seroquel illegal marketing settlement, 563
Shire, FDA violation letter, 600
Social media, guidance for industry, 259; FDA guidance sought, Special Report, 297
Staple peptide therapeutics, 1121
Targeting by FDA, misleading promotions, 73
Testopel promotional materials, 530
Trends
—Diagnostic imaging technology usage, 250
—Digestive conditions, drug use up, 187
—Global market growth, 529
—Health reform, effect on markets, 527
—Prescription drug sales up in 2009, 466
—Psychotropic drugs usage, 44
—Use of prescription drugs up, 1155
USPS Saturday deliveries, 631
VA, drug promotion, 597
Vermont
—Disclosure requirements for drug firms, 656
—Spending by drug firms, 465
Victoza, 218
Vioxx purchasers suit, no class certification (Cal. Ct. App.), 13; denial upheld (Cal.), 457
Vivitrol welcome kit at issue, 1475
VVD treatment, 662
Warning letters from FDA, 365
Workforce cuts for pharmaceutical industry, 1324
Xifaxan for overt hepatic encephalopathy, 692
Zetia generic, 603

MARKETING —Contd.

Zipsor, 471
Zirgen, 568

MASSACHUSETTS

E-prescriptions, leading state, 1259
Gift disclosure report, 1521
Pricing
—Actavis inflated settlement (D. Mass.), 314
—False claims overcharging settlement (N.D. Ill.), 1213
—Merck false price reporting (D. Mass.), 1274
—Mylan inflated settlement (D. Mass.), 1430
—Par settlement (D. Mass.), 1613
—Watson settlement (D. Mass.), 208
—Workers comp overcharges settlement (Mass. Super. Ct.), 1156
Therapeutic Discovery Project Program credits pushed, 819

MEDICAID

Avandia, Utah suit (Utah Dist. Ct.), 1466
Average wholesale price
—Mass. BCBS, dismissal (U.S.), 1272
—Miss. misrepresentation suit (Miss.), 517
—Qui tam relator as original source (D. Mass.), 155
—S.C. settlements, pharmacies held harmless, 787
—Utah suit against firms dismissed (Utah Dist. Ct.), 271
Dual eligibles, financial relief for states from HHS, 251
Enhanced funding, bill signed, 1059
False claims
—Defending state suits, BNA Insights, 1533
—Eon Labs settlement (D. Mass.), 232
—Pfizer off-label marketing and kickbacks suit dismissal (D. Mass.), 1214; appeal (1st Cir.), 1398
—Pharmacy owner (D. Mass.), 1187
—Pricing. *See* Pricing, *this heading*
—Raplon suit dismissal (3rd Cir.), 182
—Rebate action dismissal (D. Md.), 1143
FY2011 budget proposal, 165
Generic drugs
—Rates, GAO report, 1628
—Savings and switching, 930; substitutions, 996
Geographic variation in spending, 794
Health reform. *See* LEGISLATION, FEDERAL, HR 3590
Matching funds. *See* LEGISLATION, FEDERAL, HR 1586, HR 4213, S 3000
Natl. Drug Code Directory, 1512
N.C. preferred drug list, 363
OTC coverage
—Colo., 687
—New York, 1284
Oversight HHS IG work plan, 1281
PBM changes, savings, 1592
Pharmacist reimbursement, GAO report, 18
Pricing
—Idaho
— —Actavis settlement (Idaho Dist. Ct.), 714
— —Sandoz settlement (Idaho Dist. Ct.), 1341
—Iowa AWP suit dismissal (D. Mass.), 1465
—La. overcharges (La. Dist. Ct.), 1430
—Mass. overcharging settlement (N.D. Ill.), 1213
—Merck settlements with U.S., Cal., Fla., 21
—Mich. overcharging settlement (N.D. Ill.), 1213
—N.Y. AWP suit dismissal (D. Mass.), 1465
—Part B price substitution, 1407
—Protonix overcharges (D. Mass.), 646
—Teva settlements, 189
—U.S. trade policy and negotiation limits, 290
—Withdrawal of pricing rules proposed, 1149; final rule, 1435
Rebates
—Guidance from CMS, 560
—Reform provisions, 469; effect of reform, 564; effect of new rules, 1114
—Uncollected drug rebates, HHS IG report, 393
—Unit rebate amounts calculations, 686

Reconciliation bill. *See* LEGISLATION, FEDERAL, HR 4872

Reimbursement cuts

—Cal. rate cuts
— —Chain stores suit, no injunction (9th Cir.), 515
— —Pharmacist group suit, cuts enjoined (9th Cir.), 319; suits in 4 states, 484
—Minn. pharmacy cuts challenge (D. Minn.), 234; access issues, 484
—Miss. pharmacy cuts rescinded, 822
—N.Y. rate cuts challenge (N.D.N.Y.), 484
—Wash. rate cuts challenge (W.D. Wash.), 484
Reimbursement rule revisions supported, 1321
Reporting drug data, HHS IG enforcement, 1251
Technical corrections. *See* LEGISLATION, FEDERAL, HR 5712
Wash. Walgreens decision postponement, 213; will stop filing prescriptions, 399
W.Va. E-prescription initiative, 1350

MEDICAL DEVICES

Inhalers and ozone-depleting substances, 496

MEDICARE

Renal dialysis payment system, 992; ESRD drug costs, 1227
Technical corrections. *See* LEGISLATION, FEDERAL, HR 5712

MEDICARE ADVANTAGE

Maximum out-of-pocket liability, 464
Rate freeze for 2011, 462

MEDICARE DRUG COVERAGE

Ed. Note: Entries at this heading refer to Medicare Part D unless otherwise indicated.
Approval by FDA requirement, CMS warning, 9
Cardiovascular agent use, AHRQ report, 359
Catastrophic coverage, GAO report, 288
Coverage gap
—Accords signed, 1254
—Discount concerns, 752
—Fines for drugmakers, 683
—Options for drugmakers, 655
—Provisions to close, 462
Data sharing, FDA pact with CMS, 953
Dialysis, CMS rule, 426
Discounts
—Codes for drugmakers, 1316
—Effect, 1518
—Manufacturers pact from CMS, 1028
—Program guidelines, 595
Dual eligibles, financial relief for states, 251
Elimination of plans, 1255
Formulary
—Access, Aetna enrollment, 497
—Guideline changes, 1288
—Tiers, 1527
Generic drug use and spending, CBO report, 1189
Hospital acquisition costs, 1372
Invalid identifiers, HHS IG report, 897
Least costly drug option, HHS authority (D.C. Cir.), 9
Meaningfully different plans, 1154
Off-label use. *See* LEGISLATION, FEDERAL, HR 5732
Oversight HHS IG work plan, 1281
Prices
—Average wholesale price suit, qui tam relator as original source (D. Mass.), 155
—Negotiated prices, authority urged, 282
—Specialty-tier drugs, price concessions, 357
Provence
—CMS panel supports, 1515
—National coverage analysis, 896
Reporting drug data, HHS IG enforcement, 1251
Savings from adjusted rates, HHS IG report, 897
Success of program, MedPAC report, 1437
Vt., rebates and drug assistance program, 789
Waiver of overpayment (D.C. Cir.), 815

MERGERS AND ACQUISITIONS

Abbot purchase of Piramal branded generics unit, 690
Alcon complaint against Novartis (S.D.N.Y.), 920; pact announced, 1592
Astellas and OSI, 662; completion, 759
BioMarin and ZyStor, 1097
Biovail and Valeant, 828
Bristol-Myers and ZymoGenetics, 1160
Cardinal Health purchase of Healthcare Solutions, 793
Cephalon and Mepha, 501
CVS Caremark, antitrust issues, 1472
Emergent and Trubion, 1097
Endo
—Penwest purchase, 1064
—Qualitest purchase, 1260
Enforcement, FTC-DOJ reviews, 1348
Genzyme
—Bioenvision, disclosure issues (2nd Cir.), 492
—LabCorp, sale of unit to, 1563
—Sanofi offer, 1159
GSK and Nanjing MeiRui, 1564
Horizontal merger guidelines, 592
Hospira and Javelin, 532
Hypertension drug, 633
IMS Health purchase, EU clearance, 171
Insmid and Transave, 1564
Lilly
—Alnara purchase, 901
—Avid Radiopharmaceuticals, 1442; purchase completed, 1635
Lysteda, 633
McKesson to buy US Oncology, 1412
Medco and United BioSource, 1097
Merck purchase of SmartCells, 1563
Mylan to buy Bioniche Pharma, 966; completed, 1161
Novartis bid for Alcon, EU conditions, 1067; divestment required, 1090
Noven marketing rights, 1063
Pfizer
—FoldRx, 1161
—King Pharmaceuticals merger, 1324
—Laboratorio Teuto Brasileiro, 1381
—Wyeth merger challenge (N.D. Cal.), 516
Ramius and Cypress Bioscience, 1194
Sandoz and Oriol, 531
Shire and Movetis, 1034
Teva
—Merckle purchase, 1037
—Ratiopharm purchase, 400; EU conditions, 1066
Valeant Brazilian purchase, 531

MERIDIA

Diet drug, challenge to generic (D. Del.), 36
Obesity drug, new certification sought (N.D. Ill.), 977
Public Citizen seeks ban, 328
Stroke and heart attack risk, 1158
Withdrawal considered by FDA panel, 1231; Abbott to pull, 1319

METAXALONE

Muscle relaxant, generic blocked (D.N.J.), 641

METOCLOPRAMIDE

Black box warning (M.D. Fla.), 1623
Branded maker liability (D. Vt.), 1467
Experts and causation (S.D. W.Va.), 1554
Failure to warn claims (U.S., rev sought), 677; (brief filed), 1086; DOJ position (brief filed), 1428; (rev grant), 1577
Gastroesophageal drug blamed for tardive dyskinesia (5th Cir.), 1367

METOPROLOL

Blood pressure drug, preemption of liability claims (E.D. Mo.), 66

METZOLV ODT

GERD treatment, FDA warning on promotional materials, 469

METVIXIA

Actinic keratosis treatment patent extension, 617;
BNA Insights, 762

MEXICO

Antitrust, firms fined, 295; appeal denied, 869
Biocomparable approvals, 1065

MICHIGAN

False claims overcharging settlement (N.D. Ill.), 1213

MIDODRINE

Hypertension drug approval withdrawal, 1096; public hearing sought, 1190

MINNESOTA

Canadian drug access program termination, 72
Medicaid pharmacy cuts challenge (D. Minn.), 234;
access issues, 484
Oral chemo parity, 657

MIRALAX

Antitrust, laxative direct purchasers' suit (D. Del.), 678

MIRAPEX

Gambling losses based on drugs (D. Minn.), 1185

Generic

—Antitrust dispute (W.D. Pa.), 413
—Approval, 1381
—Enjoined (M.D. Fla.), 1020
—Mylan agreement (D.N.J.), 1106
Parkinson's drug patent extension limits (Fed. Cir.), 619

MIRCERA

Anemia drug patent settlement (D. Mass.), 5

MISSISSIPPI

Average wholesale price misrepresentation suit (Miss.), 517
Pharmacies, Medicaid cuts rescinded, 822
Seroquel suit remanded (N.D. Miss.), 1343

MONTANA

Canadian drug imports, 362; pilot program with N.D., 525

MOTAVIZUMAB

Respiratory virus drug application, 45; FDA panel rejects, 757; more data sought, 1162

MOTRIN

Pain drug labeling, preemption of Tex. law (N.D. Tex.), 157

MOVIPREP

Colonoscopy preparation settlement (D.N.J.), 1144

MUCINEX

Chest congestion drug, generic no infringement (W.D. Mich.), 200; vacated, 1051

MYLOTARG

Leukemia drug withdrawal, 824

N**NAMENDA**

Alzheimer's drug infringement by generic settlement (D. Del.), 7
Dementia drug, generic patent settlement (D. Del.), 978

NANOTECHNOLOGY

Safety. *See* LEGISLATION, FEDERAL, S 2942

NAPROXINOD

Arthritis drug, FDA panel rejection, 658

NAROPIN

Anesthetic infringement ruling vacated (Fed. Cir.), 1463

NATAZIA

Contraceptive approval, 632

NATIONAL INSTITUTES OF HEALTH (NIH)

Collaboration with FDA, 245
Comparative effectiveness research grants, 359
FY2011 budget proposal, 165

NEOPROFEN

Anti-inflammatory drug recall, 1034

NEURONTIN

Causation, expert testimony (D. Mass.), 1146
Epilepsy drug and suicide, widow's suit (M.D. Tenn.), 322; expert testimony, 627; settlement, 682
Generic approvals, 760
Off-label promotion, jury verdict (D. Mass.), 416; Cal. sales, 1426

NEUTROVAL

Neutropenia drug, biologics license application, 170

NEW YORK

Copy limits, 1284
Financial relationships between providers and drug and device makers, 169
Formulary specialty tiers, 755; banned, 1284
Medicaid
—AWP suit dismissal (D. Mass.), 1465
—OTC coverage, 1284

NEXIUM

Deceptive marketing suit (D. Del.), 645
Heartburn drug
—Dr. Reddy's generic challenge (D.N.J.), 1431
—Ivax generic patent settlement (D.N.J.), 59
Response letter, 729

NIGERIA

Trovan clinical trial injuries (U.S., brief filed), 719;
(rev den), 852; limited discovery (S.D.N.Y.), 1345

NIMODIPINE

Subarachnoid hemorrhage drug, FDA warning, 1029

NORFLOXACIN

Antibiotic, Canadian generic delay (Fed. Ct.), 502

NORTH CAROLINA

Medicaid preferred drug list, 363

NORTH DAKOTA

Canadian drug imports, pilot program with Mont., 525

NORVASC

Canada, antihypertensive patent invalid, 1065

NORVIR

Invirase-Norvir and abnormal heart rhythms, 253
Protease inhibitor, predatory pricing suit (N.D. Cal.), 781; mandamus denied (9th Cir.), 1246

NSAID

Nonsteroidal anti-inflammatory drug design defect (D.N.H.), 986

NUVIGIL

Apotex generic challenge (D.N.J.), 1107
Watson generic of sleep disorder drug, challenge (D. Del.), 36

O**OC TAGAM**

Primary humoral immunodeficiency drug recall, 1259

OFF-LABEL USE

Actimmune, proof of damages (N.D. Cal.), 1462; DOJ memo, 1616
Aransep suit dismissal (9th Cir.), 1363
FDA limits challenge (D.D.C.), 519
Kaletra kickback claims (D. Mass.), 943
Kos settlement (M.D. La.), 1550
Marinol promotion (U.S., rev den), 815
Medicare. *See* LEGISLATION, FEDERAL, HR 5732
Neurontin promotion, jury verdict (D. Mass.), 416;
Cal. sales, 1426
Pfizer consumer fraud suit (E.D. Pa.), 988
Rapamune whistleblower suit (E.D. Pa.), 715; DOJ intervention, 1209
Rituxan, whistleblower (E.D. Pa.), 778
Topamax settlement, 584
Trileptal cases, 1269
Zyprexa, La. settlement (E.D.N.Y.), 488

OMAPRO

Cancer drug application, 397

OMNICEF

Antibiotic, no patent infringement (U.S., rev den), 59

OPANA ER

Barr Labs, painkiller generic infringement settlement (D.N.J.), 516
Impax and Sandoz generic infringement settlements (D.N.J.), 746

ORACEA

Rosacea generic blocked, 887

ORAL COLCHICINE

Gout drug unapproved uses (D.N.J.), 1397

ORAPED ODT

Corticosteroid generic infringement claim (D. Del.), 1620

OREGON

Psychologists prescription authority, 330; vetoed, 498

ORPHAN DRUGS

AEZA-108, 634
Alpha1-Proteinase Inhibitor, 191
AP24534, 294
BMN-701, 1161
Carbaglu approved, 398
Ciprofloxacin status, 368
CK-2017357, 371
Collaboration, FDA and EU, 285
ENMD-2076, 218
FDA workshop, 20
Graspa, 173
IMGN901, 335; 1122
LRX-0401, 966
MP4CO, 1476
Nefecon, 1325
Octreolin, 868
QPI-1002, 218
RG2833, 692
Sapacitabine, 902
SBC-102, 932
TOL101, 827
TXA127, 868
Workshop, FDA plans, 1316
Xifaxan for hepatic encephalopathy, 291

OXYCONTIN

False claims dismissal (4th Cir.), 417; (U.S., rev den), 1304
Product liability, out-of-state claims (N.Y. Sup. Ct.), 1278

P**PANCREASE**

Pancreatic enzyme product approved, 500

PATENTS

AIDS/HIV drug evaluation methods (U.S., rev grant), 1394
Allergan settlement (E.D. Tex.), 747
Analysis of obviousness by courts, BNA Insights, 1197
Angiomax. *See* ANGIOMAX
Antidepressant process patent invalid for obviousness (S.D.N.Y.), 809
Aricept. *See* ARICEPT
Arzerra. *See* ARZERRA
Backlog at PTO, 1254
Bardoxolone methyl, 1260
Benicar patent not invalid for obviousness, 1175; (U.S., rev sought), 1615
Biologics, Filgrastim infringement suit (E.D. Pa.), 1498
Boniva infringement claim (D.N.J.), 1087
Business methods, machine-or-transformation test (U.S.), 847; industry and practitioners react, 850
Calculations for extended patent terms challenge (Fed. Cir.), 57
Carbetocin, 1162
Cefaclor infringement claim (Fed. Ct. App.), 1327
Cenestin infringement claim (S.D.N.Y.), 776
Cialis inventorship (Fed. Cir.), 487
Cipro antitrust settlement challenge (2nd Cir.), 579; rehearing sought, 675; amended, 853
Concerta patent invalid (Fed. Cir.), 549
Copaxone infringement claim (S.D.N.Y.), 1212
Cozaar exclusivity upheld (D.D.C.), 349; FDA supports, 414
Crestor patent upheld, 883
Criteria for injunctions, BNA Insights, 870
Decline in international findings, 221
Delivery device patent extension (D.D.C.), 233
Detrol nonobviousness (D.N.J.), 156; patent upheld, 230
Diagnostic test patents (Fed. Cir.), 1608
Diovan patent extension denial in Brazil, 26
Enforcing drug patents, BNA Insights, 1447
Evista patent upheld (Fed. Cir.), 1133
Examination quality, PTO procedures, 1317
Fabrazyme. *See* FABRAZYME
Fee-setting authority for PTO, 653
Focalin infringement claims dismissal (D.N.J.), 156
Fuzeon infringement settlement (E.D.N.C.), 1246
Gemzer. *See* GEMZER
Generic drugs. *See* GENERIC DRUGS
Gianvi. *See* GIANVI
Gleevec Brazilian patent decision, 1382
Helixate FS settlement (E.D. Tex.), 273
Human rights concerns on drug access, 530
Humira. *See* HUMIRA
Hyzaar exclusivity upheld (D.D.C.), 349; FDA supports, 414
Incentivizing technologies, PTO seeks comments, 1227; criticized, 1512
India, drug patents, Analysis & Perspective, 46
Inequitable conduct test, Special Report, 1595
Intermezzo, 401
Levaquin patent extension (Fed. Cir.), 617; BNA Insights, 762; rehearing denied, 976
Licensing
—Amigal, 1416
—Antibiotics, 1529
—Cancer drugs, 760
—Danoprevir, 1326
—Esmya, 1637
—QPI-1002, 1097
—Seasonale, 623
—Seroquel, 623
Lipitor. *See* LIPITOR
Metvixia patent extension, 617; BNA Insights, 762
Mirapex patent extension limits (Fed. Cir.), 619
Mircera settlement (D. Mass.), 5
Miscalculation of term extension (D.D.C.), 202
Mydicar, 434
Naropin infringement ruling vacated (Fed. Cir.), 1463
Orange Book listing, Hatch-Waxman application, 512; rehearing denied, 1016

Plavix infringement, stay denial (S.D.N.Y.), 514; damage award, 1339
Purdue Pharma pain relief drugs settlement (W.D. Va.), 987
Qnexa patents, 331
Ranexa infringement alleged (D.N.J.), 947
Recalculation of patent term adjustments (D.D.C.), 917
Reform, Leahy's efforts, 282; substitute amendment, Special Report, 336; patent community support, Special Report, 339; industry concerns, 396; manager's amendment, 495; questions raised, Special Report, 798
Rosuvastatin infringement claims (Fed. Ct. App.), 604
Russia, collaboration with PTO, 796
Skelaxin method patent invalid as obvious (Fed. Cir.), 1014
Sleeping pill generic, inequitable conduct claims (D.N.J.), 774
Surfaxin patent extension, 1354
Sxpertise at district courts. *See* LEGISLATION, FEDERAL, HR 628
Taxotere patent invalid for obviousness (D. Del.), 1245
Temodar. *See* TEMODAR
Three-track exam system, 751
Ultram ER patent obviousness (Fed. Cir.), 743
Updated obviousness guidelines from PTO, 1165
Venture capital and Hatch-Waxman, BNA Insights, 535
Viagra. *See* VIAGRA
Viread, 173
Vyvanse exclusivity decision challenge (D.D.C.), 311; exclusivity upheld (D.C. Cir.), 1425
Written description requirement upheld (Fed. Cir.), 381
Xopenex infringement alleged (D. Del.), 945
Xyrem, 1636
Zenvia, 219
Zetia. *See* ZETIA
Zometa infringement suit (D. Del.), 982
Zymar patent invalid (D. Del.), 851
Zyprexa validity, rehearing ordered (Fed. Cir.), 1036

PAXIL

Birth defects
—Antidepressant, no summary judgment (N.D. Okla.), 10
—Confidential settlements (Pa. Ct. Com. Pl.), 865
—Fatal heart defect, limitations period (S.D. Ohio), 522
—Fraudulent joinder claim (E.D. Ky.), 1185
—Most suits settled, 959
Generic, TRO denied (D.N.J.), 1340; no injunction, 1395
Suicide risk
—Appeal dismissed (10th Cir.), 587; rehearing sought, 648
—Catholic priest's death, no summary judgment (S.D. Ind.), 490
—Failure-to-warn of suicide risk, no preemption (7th Cir.), 271
—Inadequate warning, verdict for maker (11th Cir.), 319
—Remand suits (10th Cir.), 744
—Venue change denied (E.D. Pa.), 11

PDUFA (PRESCRIPTION DRUG USERS FEE ACT) *See* USER FEES

PENNSYLVANIA

Bristol-Myers Medicaid AWP case (Pa. Commw. Ct.), 1305
J&J Medicaid AWP reporting (Pa. Commw. Ct.), 1612

PERSONALIZED MEDICINE

Holistic approach pushed by FDA chief, 284
R&D effects, 1475

PHARMACISTS AND PHARMACIES

CEO for association, 1380
Database of patient services, 171
FEHBP, CVS generic drug prices, 217
Medicaid reimbursement
—Cuts challenge dismissal (D.D.C.), 1580
—False claims (D. Mass.), 1187
—GAO report, 18
—Walgreens Wash. decision postponement, 213
Merger of CVS Caremark, antitrust issues, 1472
Privacy
—Protected health information, CVS alleged misuse (S.D. Tex.), 1307
—Rite Aid HIPAA settlement, 992
Specialty pharmacy teams, CVS survey, 567

PHARMACY BENEFITS MANAGEMENT (PBM)

D.C. law preempted (D.C. Cir.), 913
Express Scripts, brand name drug pricing suit dismissal (11th Cir.), 646
Genetic benefit management, 758
Medicaid savings, changes, 1592
Transparency
—Grassley seeks feedback, 360
—Rectification of PBMs, 1323
Utah, itemized forms, 1284
Walgreens out of CVS network, 756; CVS announcement, 792; new agreement, 826

PHENSERINE

Alzheimer's drug, class securities fraud claim dismissal (2nd Cir.), 419

PHILIPPINES

Lipitor generic retail sales, 221; reconsideration sought, 258

PHOSLO GELCAPS

Generic challenge (D. Mass.), 1145

PIRFENIDONE

IPF drug priority review, 43

PIXUVRI

Cancer drug application, 397; appeal, 1561

PLAVIX

Antiplatelet drug effectiveness, boxed warning, 367
BCBS placement in highest tier (3rd Cir.), 779
Patent infringement, stay denial (S.D.N.Y.), 514; damage award, 1339

POTIGQ

Partial-onset seizure drug, FDA panel vote, 1095

PRADAXA

Stroke drug, FDA panel vote, 1232; approved, 1354

PRANDIN

Anticompetitive conduct suit (D. Minn.), 1580
Diabetes drug purchaser class action (E.D. Mich.), 715
Patents
—Claims dropped (S.D.N.Y.), 1616
—Infringement claim (E.D. Mich.), 1303
—Orange Book listing, Hatch-Waxman application, 512; rehearing denied, 1016

PREGABALIN

Anticonvulsant, no declaration of confidentiality, 571; notice of allegation, 906

PREMARIN

HRT blamed for breast cancer (E.D. Ark., D. Minn.), 1219
Transfer of breast cancer suit (D. Minn.), 1433

PREMPRO

Class action not time-barred (E.D. Va.), 857
Expert witnesses (D.P.R.), 1556

PREMPRO —Contd.

Foust breast cancer suit (Pa. C.P.), 278
 Mich. fraud exception (E.D. Mich.), 1309
 Singleton breast cancer suit (Pa. C.P.), 278
 Torkie-Tork breast cancer suit (E.D. Va.), 1583
 Wilson breast cancer suit (E.D. Ark.), 1583

PRESCRIPTION DRUG USERS FEE ACT (PDUFA) *See* USER FEES**PREVNAR 13**

Biologics application, 44

PRICING

AIDS drug pricing suit (C.D. Cal.), 1502
 ASP, late data from firms to CMS, 211
 AstraZeneca settlement, 826
 Brand-name drugs price hikes, 659; generics effect, 757
 Brazil drug price control adjustment, 372
 Cardinal Health overcharges settlement, 930
 Ceiling prices
 —Federally funded medical clinics (9th Cir.), 34; (U.S., rev grant), 1243; (brief filed), 1618
 —TRICARE, implementation of Federal Ceiling Prices, 210
 Conn. pricing settlement (D. Mass.), 1340
 Consolidated suit, inflated pricing claims, N.Y. law violations (D. Mass.), 154
 Dispute resolution, HRSA seeks comments, 1226
 Exclusivity and drug costs, 1441
 Expediting Bristol-Myers settlements (D. Mass.), 1503
FEHBP
 —CVS generic drug prices, 217
 —Transparency. *See* LEGISLATION, FEDERAL, HR 4489
 Health reform effects, CBO report, 1437
 India, price controls, 1163
J&J
 —Overcharging suit (C.D. Cal.), 1621
 —Reporting prices (Pa. Commw. Ct.), 1612
 Massachusetts
 —Actavis inflated settlement (D. Mass.), 314
 —False claims overcharging settlement (N.D. Ill.), 1213
 —Merck false reporting (D. Mass.), 1274
 —Mylan inflated settlement (D. Mass.), 1430
 —Par settlement (D. Mass.), 1613
 —Watson settlement (D. Mass.), 208
 —Workers comp overcharges settlement (Mass. Super. Ct.), 1156
Medicaid
 —Idaho
 — — Actavis settlement (Idaho Dist. Ct.), 714
 — — Sandoz settlement (Idaho Dist. Ct.), 1341
 —Iowa AWP suit dismissal (D. Mass.), 1465
 —Mass. overcharging settlement (N.D. Ill.), 1213
 —Merck settlements with U.S., Cal., Fla., 21
 —Mich. overcharging settlement (N.D. Ill.), 1213
 —N.Y. AWP suit dismissal (D. Mass.), 1465
 —Part B price substitution, 1407
 —Protonix overcharges (D. Mass.), 646
 —Teva settlements, 189
 —U.S. trade policy and negotiation limits, 290
 —Wis., Boehringer settlement (Wis. Cir. Ct.), 553
 —Withdrawal of pricing rules proposed, 1149; final rule, 1435
 Medicare inflated AWP settlements, 1549
 Qatar price control relief, 1356
 Russia, vitally important drugs, 1446
 Steep hikes, GAO report, 68
 Switzerland, price cuts for health insurance system, 295
 Watson inflated price reporting, Mass. settlement (D. Mass.), 208
PRIOSEC
 Extra damages denied (S.D.N.Y.), 811
 Heartburn drug infringement by generic (Fed. Cir.), 5

PRIVACY AND CONFIDENTIALITY

HITECH Act privacy rules and drugmakers, BNA Insights, 1038
 Protected health information, CVS alleged misuse (S.D. Tex.), 1307
 Rite Aid HIPAA settlement, 992
 State restrictions
 —Me. prescribing data sales limits (1st Cir.), 1049
 —Vt. data mining law unconstitutional (2nd Cir.), 1496; (U.S., rev sought), 1614; BNA Insights, 1643

PROCRIT

Anemia drug, qui tam suit partial dismissal (U.S., rev sought), 37; Solicitor Gen. input sought, 231; (rev den), 810
 J&J consumer claims (D. Mass.), 1209
 Recall, 1258

PRODUCT LIABILITY

Accutane. *See* ACCUTANE
 Antibiotics, generic and vision loss (M.D. Ga.), 355
 Avandia. *See* AVANDIA
 Baycol and muscle damage, exclusion of expert (8th Cir.), 354
 Bisphosphonates
 —Jawbone deterioration (M.D.N.C.), 1400
 —Osteonecrosis (N.J. Super. Ct.), 1310
 Cymbalta suicide warning claim (D.S.D.), 1310; summary judgment for maker, 1364
 Darvocet and heart attack (E.D. La.), 1624
 Digitek. *See* DIGITEK
 Duragesic wrongful death claim (Tex. App.), 457
 Effxor and suicide, learned intermediary (W.D. Pa.), 277
 Embeda, 239
 Fentanyl. *See* FENTANYL
 Fosamax. *See* FOSAMAX
 Hepatitis after colonoscopy (Nev. Dist. Ct.), 625
HRT. *See* HORMONE REPLACEMENT THERAPY (HRT)
 Infusion pump pain drugs (D.R.I.), 783
 Lamisil and skin disease (D.N.J.), 1218
 Learned intermediary defense, BNA Insights, 832
 Levaquin. *See* LEVAQUIN
 Metoclopramide. *See* METOCLOPRAMIDE
 Metoprolol, preemption of liability claims (E.D. Mo.), 66
 Motrin labeling, preemption of Tex. law (N.D. Tex.), 157
 Neurontin and suicide, widow's suit (M.D. Tenn.), 322; expert testimony, 627; settlement, 682
 Nsaid design defect (D.N.H.), 986
 Ortho-Evra patch labeling (N.D. Ohio), 160
 Pain patch
 —Alza, fatal overdose (S.D.N.Y.), 237
 —Mylan, blamed for death (E.D. Mo.), 555
 Pain pumps
 —Cal. suit dismissal (C.D. Cal.), 488
 —Continuous infusion of anesthetics (D. Minn.), 890
 —Exemplary damages permitted (D. Colo.), 1365
 —Fraudulent concealment claims (W.D. Pa.), 1366
 —Summary judgment for anesthetic makers (S.D. Ind.), 321
 —Vt. suit dismissal (D. Vt.), 161
 Paxil. *See* PAXIL
 Phenylpropranolamine and neurological ailments (Iowa), 235
 Preemption of failure-to-warn claims (6th Cir.), 1501
 Prempro. *See* PREMPRO
 Provera and breast cancer (Pa. Super. Ct.), 64
 Prozac suicide warning claim against generic (C.D. Cal.), 455
 Public disclosure, draft FDA proposal, BNA Insights, 1068
 Redux and valvular heart disease (Pa. Super. Ct.), 1022
 Reglan. *See* REGLAN
 Remicade direct advertising, no learned intermediary (Tex. App.), 317
 Requip blamed for gambling (5th Cir.), 386

Risperdal and diabetes (La. Parish Ct.), 1342
 Seizure drug and skin reaction (S.D. Miss.), 1277
 Serquel. *See* SEROQUEL
 Sulindac blamed for blindness and skin reaction (D.N.H.), 1183
 Transdermal system, Okla. consumer law (S.D. W. Va.), 718
 Trasylol. *See* TRASYLOL
 Vioxx not fit for purpose, Australia, 372
 Wellbutrin side effects, no preemption (E.D. Pa.), 745; failure-to-warn claim, 854
 Zyprexa. *See* ZYPREXA

PROLIA

Osteoporosis drug approved, 729

PROMACTA

ITP drug and liver disease, 659

PROPOFOL

Anesthetic withdrawn, 730

PROPOXYPHENE

Pain drug withdrawal, 1523

PROPYLTHIOURACIL

Hyperthyroidism drug and liver damage, 566

PROSCAR

Prostate cancer drug, new indications, 1561

PROTONIX

Acid suppressant drugs, Medicaid overcharges suit (D. Mass.), 646
 False advertising suit dismissal (E.D. Mich.), 313
 Generic blocked (D.N.J.), 1105; ANDA accepted, 1355
 Heartburn drug patent valid (D.N.J.), 584; upheld, 941

PROTOPAM CHLORIDE

Poisoning treatment pediatric use approval, 1194

PROVENGE

Medicare
 —CMS panel supports, 1515
 —National coverage analysis, 896
 Prostate cancer drug approval, 598

PROVERA

HRT and breast cancer (Pa. Super. Ct.), 64

PROVIGIL

Discovery ordered (D.D.C.), 942
 Narcolepsy generic, subpoena upheld (D.D.C.), 1080
 Settlements in antitrust suit challenge (E.D. Pa.), 412
 Sleep disorder drug antitrust suit (N.D. Ohio), 748

PROZAC

Suicide warning claim against generic (C.D. Cal.), 455

PTO (PATENT AND TRADEMARK OFFICE)

See generally PATENTS

PUERTO RICO

Tax on foreign firms, 1410

PULMICORT

Respiratory generic blocked (Fed. Cir.), 1391

Q**QATAR**

Price control relief, 1356

QNEXA

Application, 24; FDA panel opposition, 961; more data sought, 1409; briefing document, 1591
 Obesity drug patents, 331

QUALAQUIN

Malaria drug unapproved use, 929
Risk management plan approval, 1062

R

RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS (RICO) ACT

Off-label use, Pfizer relief (D. Mass.), 60

RANEXA

Angina drug infringement alleged (D.N.J.), 947

RAPAMUNE

Marketing unapproved uses, whistleblower suit (E.D. Pa.), 1342
Transplant drug, promotion for unauthorized uses, 784

RAPLON

Neuromuscular blocking agent, false claims suit dismissal (3rd Cir.), 182

RE METHYLPHEN

Advertising, Lanham Act suit (D. Md.), 1081
Urinary antiseptic advertising, Lanham Act suit (D. Md.), 1081

RECALLS *See* SAFETY

REDUX

Diet drug and valvular heart disease (Pa. Super. Ct.), 1022
Strict liability claim rejected (Pa. Super. Ct.), 1056
Weight loss drug, no preemption (6th Cir.), 1146; no review, 1345

REGLAN

Brand-name maker liability
—Ark. suit (W.D. Ark.), 948
—La. suit (M.D. La.), 1401
—Md. suit (D. Md.), 1468
—Tex. suit (E.D. Tex.), 588
Consolidated appeal of generic preemption suits (6th Cir.), 916
Failure-to-warn suit, no preemption (N.D. Ohio), 274
Heartburn generic blamed for movement disorder (N.D. Ga.), 420
Tardive dyskinesia blamed on drug (S.D. Ala.), 557

REGN475/SAR164877

Pain drug clinical hold, 1633

REMICADE

Arthritis drug direct advertising, no learned intermediary (Tex. App.), 317
Lung disease blamed on drug (N.D. Ohio), 1469

REMS *See* RISK EVALUATION AND MITIGATION STRATEGY (REMS)

RENVELA

Kidney drug, generic challenge (D. Md.), 717

REPLAGAL

Fabry disease drug application, 23

REQUIP

Parkinson's drug blamed for gambling (5th Cir.), 386

RESEARCH AND DEVELOPMENT (R&D)

Antibacterial drug manufacturing, FDA guidance, 750
Bayer and OncoMed, 828
Boehringer and MacroGenics, 1380
Business model criticized, 1096
Children's drugs in development, 467
Collaboration between FDA and NIH, 245
Conflicts of interest rules, development of drugs affected, 1377

Diabetes drugs in development, 690; TransTech and Forest, 759; Metabolex and OMJPI, 827;
Boehringer and Neurocrine, 828; Metabolex and Sanofi-aventis, 868

Elagolix, 794

Exclusivity and drug costs, 1441

Expiration of patents, effect on research, 43

Hepatitis

—Draft guidance from FDA, 1188

—Drug access, 591

Improving development, recommendations, 468

Injectable medications, 602

Investment for 2009, estimate, 369

IPX066, 1637

KNS-760704, 1122

Mental health drugs in development, 963

MicroRNA-targeted drugs, 827

Misconduct in research, anesthesiologist, pain drug data fabrication guilty plea (D. Mass.), 280; sentenced, 858

Modern drug design, Scripps research, 1325

Nitto Denko and Quark collaboration, 965

Nonclinical lab study rule, 1627

Onfigin SPA, 45

Outsourcing approaches, 1412

Pfizer and Washington Univ. collaboration, 661

Posidur, 759

Qualification of drug development tools, 1371

Rare pediatric diseases, Senate hearing, 954

REGN475/SAR164877 clinical hold, 1633

Regulatory workload, 366

Therapeutic Discovery Project Program

—IRS accepts applications, 819

—Mass. pushes credits, 822

Zerenez SPA, 45

RESTORIL

Insomnia drug patent obvious, 586

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

Comments on FDA draft guidance, 41

RISPERDAL

Antipsychotic and diabetes (La. Parish Ct.), 1342

RITUXAN

Leukemia drug approved, 254
Off-label use, whistleblower (E.D. Pa.), 778

ROSUVASTATIN

Cholesterol drug infringement claims (Fed. Ct. App.), 604

RUSSIA

Circulation of medicines law, 534
Collaboration with PTO, 796
Importing drugs, new rules, 1328
Improved intellectual property protection, 1356
Strategic medicines list, 933
Vitality important drugs, 1446

S

SAFETY *See also* FOOD AND DRUG ADMINISTRATION (FDA); WARNINGS

Active pharmaceutical ingredients, manufacturing violations, 255

Actos and bladder cancer risk, 1233

Adulterated or misbranding products, BNA Insights, 1002

Advair Diskus inhalers stolen, 963

Adverse events. *See* ADVERSE EVENTS

Anemia drugs

—Cancer patients, 1377

—FDA meeting, 70; approval of risk management program, 209

Anzemet heart risk, 1632

Apotex manufacturing violations, 499

Aransep kidney disease risk, 1353

ARBs and cancer, 952

Authority expansion for FDA, 1316

Avandia heart attack risk, Senate report, 242; access restricted, 1229

Avon warning letters from FDA, 431

Beehive Botanicals, unapproved drug seizure, 470

Bisphosphonates and femur fractures, 1192

Bristol-Myers P.R. facility, 1192

Canada

—Improvements urged, 1531

—Side effect reporting, 830

Cleviprex recall, 24

Clinical trials reporting, FDA final rule, 1251

Combination drugs, good manufacturing practices, FDA proposed rule, 186

Communication, FDA practices, 1111

Computerized order systems medication errors, 1063

Contamination at Pfizer facility, jury award for fired scientist (D. Conn.), 458

Coumadin recall, 929

Counterfeit drugs. *See* COUNTERFEIT DRUGS

Cubicin and pneumonia, 1030

Diabetes drug risks, 1120

Drugs.com collaboration with FDA, 725

Electronic records and signatures, industry compliance, 925

Enforcement. *See* LEGISLATION, FEDERAL, S 3690

Epogen recall, 1258

Evamist, adverse effects on children, 1030

Fentanyl recall, 1379

Final rules from FDA, 1625

Foreign inspections increased by FDA, 1370

FY2011 FDA budget proposal, 164

Gabitril, 1355

GammaGard lots withdrawn, 759

Generic drug impurities, FDA guidance, 1517

Genzyme manufacturing practices, FDA enforcement action, 399; draft consent decree, 527; final consent decree, 679; Allston operations end, 1525

GlaxoSmithKline

—Adulterated drugs, penalties (D. Mass.), 1363

—Manufacturing deficiencies, settlement, 959

Global drug safety, Democrats proposal, 1223

Globalized drug production and FDA, 326

GnRH and diabetes, 591

Heparin contamination, report, 596; recall, 1414; FDA criticized, 1436

Hospital admissions for drug-related conditions, 1372

Hylenex recall, 660

Imported drugs, Senate hearings, 327

Inhalers and ozone-depleting substances, 496

IriSys San Diego facility, 1232

IUDs, unapproved sales (Tex. Dist. Ct.), 1368

IV bag contamination, 730

K-V Pharma return to drugmaking, 1190

Kapidex name change, 333

KV Pharmaceutical settlement over reporting (E.D. Mo.), 270

Lamictal and aseptic meningitis, 1095

Lipitor recall, 1414; another lot recalled, 1635

Lipodissolve, FDA warning stars, 461

Meridia. *See* MERIDIA

Methotrexate injection recall, 1413

Metozolv ODT, FDA warning on promotional materials, 469

Metronidazole injection recall, 661

Mont. drug maker, unapproved new drugs, 1346

Mylotarg withdrawal, 824

Names of drugs, FDA guidance, 186

Nanotechnology. *See* LEGISLATION, FEDERAL, S 2942

NeoProfen recall, 1034

Nimodipine, FDA warning, 1029

Nitroglycerin, FDA warning letters, 364

Octagam recall, 1259

Ohm Labs manufacturing practices, FDA warning letter, 189

Opioids, proposed risk plan from FDA, 859; risk evaluation and mitigation strategy, 990

SAFETY—Contd.

Osteoporosis drugs and femur breaks, FDA review, 358
 Patient medication information, FDA framework, 1153
 Perrigo manufacturing practices, 728
 Physician information, FDA draft guidance, 1473
 Posting of safety reports by FDA, 784
 Postmarketing studies, IOM report, 925
 Pregnancy, FDA research collaboration, 42
 Procrit recall, 1258
 Promacta and liver disease, 659
 Propofol withdrawn, 730
 Propoxyphene withdrawal, 1523
 Proton pump inhibitor drugs and fracture risk, 685
 Quaaluan. *See* QUALAQUIN
 Radiofrequency ID for drugs, compliance guide, 1628
 Rapamune
 —Marketing unapproved uses, whistleblower suit (E.D. Pa.), 1342
 —Transplant drug, promotion for unauthorized uses, 784
 Regulatory agenda for FDA, 592; outlined, 630
 REMS, comments on FDA draft guidance, 41; FDA reviews comments, 209
 Safe Use Initiative, FDA program, 1471
 Sentinel Initiative, FDA safety monitoring system, 67;
 Harvard Pilgrim contract award, 67; workshop planned, 1559
 Seroquel. *See* SEROQUEL
 Shire inspection, 25
 Sodium bicarbonate injection recall, 1635
 Stakeholder seek clarity in risk evaluation and mitigation strategy, 991
 Stalevo. *See* STALEVO
 Standardized medication information, FDA approval, 1252; to move forward, 1315
 Standardized numerical identifier, FDA guidance, 432
 Statin risk, 867
 Sun Pharma N.J. facility, 1157
 Tainted drug imports, Grassley query to FDA, 211
 Tessalon accidental ingestion, 1593
 Transdermal delivery systems residual drug substances, 1030
 Tri-Med drug seizure, 1379
 Tygacil, mortality risk, 1158
 Tysabri infection risk, 216
 Unapproved drugs and manufacturing practices, FDA warnings, 1000
 Valcyte dosing recommendations, 1191
 Vytorin cancer link, 21
 Weight loss drugs and liver damage, 724
 Xibrom, FDA warning letters, 364; BNA Insights, 473
 Zocor and rhabdomyolysis, 400

SEASONALE

Contraceptive license, 623

SEASONIQUE

Contraceptive generic infringement claim (D. Nev.), 454

SECURITIES

Biovail ex-execs, SEC fraud charges (S.D.N.Y.), 817
 Board minutes, access limits (N.J. Super. Ct. App. Div.), 1147
 Bristol-Myers, ex-exec alleged financial fraud (3rd Cir.), 491
 Celebrex, investors suit (U.S., rev den), 589
 Cephalon shareholder's suit (3rd Cir.), 1622
 Harvard Scientific misstatements (7th Cir.), 1250
 Hedge fund insider trading
 —French physician (S.D.N.Y.), 1401
 —Pharma exec (E.D. Pa.), 1148
 Lilly overseas marketing probe, 252
 Matrixx Initiatives fraud class action (U.S., rev grant), 856
 Medicis investor suit dismissal (D. Ariz.), 15
 Omnicare investor suit dismissal (U.S.), 1433
 Rigel Pharmaceuticals class suit dismissal (N.D. Cal.), 38

Schering-Plough settlement approval (D.N.J.), 39
 Vioxx shareholders' securities fraud suit (U.S.), 554

SEROQUEL

Advertising, FDA says materials misleading, 1062
 Antipsychotic diabetes suits
 —Mass settlement agreement in place, 1062
 —Summary judgment for maker (11th Cir.), 521
 —Time-barred consolidated suits (Del. Super. Ct.), 1249
 —Verdict for maker (N.J. Super. Ct.), 387
 Illegal marketing settlement, 563
 Miss. fraud suit remanded (N.D. Miss.), 1343

SIMCOR

Cholesterol drug generic (D. Del.), 623

SKELAXIN

Attorneys fees denial (E.D.N.Y.), 1276
 Muscle relaxant method patent invalid as obvious (Fed. Cir.), 1014

SOLODYN

Generics
 —Acne drug, Mylan generic settlement (D. Del.), 976
 —Ranbaxy generic settlement (D. Del.), 622
 New patent, 1160
 New strength, 1161

SOUTH CAROLINA

AWP settlements, pharmacies held harmless, 787

SOUTH DAKOTA

Prescription drug monitoring program, 429

SPRYCEL

Blood cancer drug approval, 1411

STALEVO

Generic, infringement settlement (D.N.J.), 813
 Parkinson's drug and cardiovascular events, 1119
 Prostate cancer link, 470

STATUTES OF LIMITATION

Fosamax liability suit untimely (S.D.N.Y.), 388
 HRT time-barred claims (D. Minn.), 1279
 Paxil and heart defect (S.D. Ohio), 522
 Prempro class action (E.D. Va.), 857
 Seroquel consolidated suits (Del. Super. Ct.), 1249
 Zyprexa time-barred suit (E.D.N.Y.), 184

STRATTERA

ADHD drug induced infringement claim (D.N.J.), 33;
 patent invalid, 1079

SULINDAC

Anti-inflammatory blamed for blindness and skin reaction (D.N.H.), 1183

SUPREME COURT, U.S.

AIDS/HIV drug evaluation methods (rev grant), 1394
 Ceiling prices, federally funded medical clinics (rev grant), 1243; (brief filed), 1618
 Celebrex, investors suit (rev den), 589
 False claims
 —FOIA and False Claims Act (brief filed), 1551
 —OxyContin suit dismissal (rev den), 1304
 Generic drugs
 —Cipro pay-for-delay settlement (rev sought), 1579
 —Metoclopramide failure to warn claims (U.S., rev sought), 677; (brief filed), 1086; DOJ position (brief filed), 1428; (rev grant), 1577
 HRT and breast cancer (brief filed), 718; (rev den), 816
 Marinol off-label promotion (rev den), 815
 Matrixx Initiatives
 —Adverse events (brief filed), 1143; (brief filed), 1470
 —Securities fraud class action (rev grant), 856
 Medicaid, Mass. BCBS AWP suit (dec.), 1272

Nigeria, Trovan clinical trial injuries (brief filed), 719;
 (rev den), 852

Omnicare investor suit dismissal, 1433

Patents

—Antitrust, unenforceable patents, direct buyer plaintiffs standing (rev den), 852
 —Benicar patent not invalid for obviousness (rev sought), 1615
 —Business method patent, machine-or-transformation test (dec), 847; industry and practitioners react, 850
 —Omnicef, no patent infringement (rev den), 59
 Procrit, qui tam suit partial dismissal (rev sought), 37;
 Solicitor Gen. input sought, 231; (rev den), 810
 Vt. data mining law (rev sought), 1614; BNA Insights, 1643
 Vioxx shareholders' securities fraud suit (dec), 554
 Yasmin patent invalid (rev den), 587

SURFAXIN

Infant Respiratory Distress Syndrome drug patent extension, 1354

SWITZERLAND

Price cuts for health insurance system, 295

T**TAMIFLU**

Generic fakes sold on web, 820

TARCERA

Cancer drug expanded use, FDA panel, 22

TARKA

Hypertension generic, no injunction (D.N.J.), 775

TASIGNA

Cancer drug, broader indications, 824
 Leukemia drug website, FDA letter, 1061

TAXATION

Biomedical applications tax credits, 684
 Excess returns, White House budget proposal, 248
 P.R. tax on foreign firms, 1410

TAXOTERE

Approval, 1064
 Cancer drug patent invalid for obviousness (D. Del.), 1245

TEFLARO

Bacterial infection treatment approval, 1411

TEMODAR

Brain tumor drug, illegal patent extension allegations (D. Del.), 316
 Unenforceability of patent (D. Del.), 119; no marketing during appeal, 385; reversed (Fed. Cir.), 1457

TERRORISM

Emergency countermeasures, HHS strategy, 1110

TESSALON

Cough capsules accidental ingestion, 1593

TESTOPEL

Testosterone promotional materials, 530

TOBI

Antibiotic false claims settlement, 586

TOPAMAX

Epilepsy drug off-label use, 584

TRADEMARKS

Zyprexa counterfeiting conviction vacated (5th Cir.), 320

TRASYLOL

Bleeding drug product liability, no remand (S.D. Ill.), 12
Class actions, suits remanded (7th Cir.), 888
Expert excluded (S.D. Fla.), 1432

TRELSTAR

Cancer drug formulation approved, 368

TREXIMET

Migraine drug, generic challenge (E.D. Tex.), 485

TRIBENZOR

Blood pressure combination approved, 998

TRILEPATL

Epilepsy drug off-label use, 1269

TROVAN

Antibiotic clinical trial injuries (U.S., brief filed), 719;
(rev den), 852

TYGACIL

Antibacterial, mortality risk, 1158

TYKERB

Breast cancer drug approval, 169

TYSABRI

MS drug, infection risk, 216

U**ULTRACET**

Painkiller patent, generic settlement (D.N.J.), 747

ULTRAM ER

Pain drug patent obviousness (Fed. Cir.), 743

UNITED KINGDOM (UK)

AstraZeneca transfers pricing settlement, 293

UROXATRAL

Prostate drug patent, generic infringes (D. Del.), 642;
patent upheld, 1106

USER FEES

Biosimilar meetings, 1560
Expiration FDA authority, 357
Ezogabine, 1161
FY2008 collections, 629
FY2011 FDA budget proposal, 164; hearings, 327;
fee hike, 1024
Generics, planned FDA meeting, 1058; preparing
negotiations, 1150; quicker approvals, 1224;
reopened comment period, 1434
PDUFA goals, FDA progress, 560
Reauthorization, industry support, 493
Small business waiver suit dismissal (N.D. Ill.), 183
Tropical disease drugs, 1228
2010 FDA agenda, 630

UTAH

Antipsychotics and diabetes (Utah Dist. Ct.), 623
Medicaid
—Avandia suit (Utah Dist. Ct.), 1466
—AWP suit dismissal (Utah Dist. Ct.), 271
PBM itemized forms, 1284

V**VACCINES**

Gardasil for anal cancer prevention, 1634
Prevnar 13 application, 44

VALCYTE

Antiviral generic settlement (D.N.J.), 1142
Transplant drug dosing recommendations, 1191

VERMONT

Data mining law unconstitutional (2nd Cir.), 1496;
(U.S., rev sought), 1614; BNA Insights, 1643
Disclosure by drug firms, 656
Marketing, drug firm spending, 465
Rebates and drug assistance program, 789

VESANOID

Leukemia drug withdrawal, 1191

VETERANS AFFAIRS (VA)

Promotion of drugs, 597

VIAGRA

Patents
—Brazilian patent expiration, 604
—Canadian patent suit (Fed. Ct.), 830; patent upheld
(Fed. Ct. App.), 1327
—Generic patent infringement claim (E.D. Va.), 454
Stroke blamed on drug (E.D. La.), 626

VIDEX

Approval, 531
HIV drug and liver disorder, 171

VIGAMOX

Eye drug generic stayed (D. Del.), 1053

VIQXX

Australia, pain drug not fit for purpose, 372
La. redhibition claim dismissal (E.D. La.), 889
Master settlement agreement challenge (5th Cir.), 983
Purchasers suit, no class certification (Cal. Ct. App.),
13; denial upheld (Cal.), 457
Shareholders' securities fraud suit (U.S.), 554

VIRGINIA

Consumer protection law and drug (W.Va.), 1619

VIVITROL

Alcohol dependence treatment labeling, 600
Application, 532; priority review, 730
Approval recommended for opioid dependence, 1231;
approved, 1323
Welcome kit at issue, 1475

VPRIV

Gaucher disease drug approval, 293

VYTORIN

Bifurcation of patent (D.N.J.), 780
Cancer link, 21
Cholesterol drug, generic
—Impax application (D.N.J.), 1107
—Mylan ANDA (D.N.J.), 7

VYVANSE

ADHD drug exclusivity decision challenge (D.D.C.),
311; exclusivity upheld (D.C. Cir.), 1425
Approval, 1476

W**WARNINGS** *See also* LABELS AND
PACKAGING; SAFETY

Exjade, 257
Invirase-Norvir and abnormal heart rhythms, 253
LABAs, FDA warning on risks, 246
Prempo. *See* PREMPRO
Prostate drugs and diabetes, 1353

WASHINGTON

Rate cuts for Medicaid challenge (W.D. Wash.), 484
Walgreens Medicaid decision postponement, 213; will
stop filing prescriptions, 399

WEIGHT LOSS PRODUCTS AND PROGRAMS

Contrave. *See* CONTRAVE
Liver damage reports, 724

Lorcaserin application, 24; goal review date, 294;
more data sought, 1378; resubmission, 1632
Meridia. *See* MERIDIA
Qnexa. *See* QNEXA
Redux. *See* REDUX
Repose law bars product liability claim (U.S., rev
den), 418

WELCHOL

Diabetes generic challenge (D. Del.), 1504

WELLBUTRIN

Antidepressant side effects, no preemption (E.D. Pa.),
745; failure-to-warn claim, 854
Antitrust
—Direct purchaser rep dismissal (E.D. Pa.), 984
—Indirect purchaser suit (E.D. Pa.), 1215
Generics
—Approval, 501; new strengths, 965
—Sham patent litigation alleged (E.D. Pa.), 1179;
reconsideration denied, 1431

WOMEN'S HEALTH

Elagolix, 794
HRT. *See* HORMONE REPLACEMENT
THERAPY (HRT)

WORKERS COMPENSATION

Mass., overcharges settlement (Mass. Super. Ct.), 1156

X**XGERVA**

Bone drug approval, 1524

XIAFLEX

Hand disease treatment approval, 170

XIFAXAN

Approval of new indication, 430
Hepatic encephalopathy drug orphan status, 291

XOPENEX

Asthma/bronchitis drug patent infringement alleged
(D. Del.), 945

XYZAL

Allergy drug generic, 1524
ANDA stayed (E.D.N.C.), 1617

Y**YASMIN**

Contraceptive infringement claim (S.D.N.Y.), 456; no
stay of approval, 1136; generic win, 1270
Invalid patent (U.S., rev den), 587
Malpractice and product liability claims (N.D. Okla.),
1510

YAZ

Combination approved, 1258
Contraceptive infringement claim (S.D.N.Y.), 456
Generic challenge (D. Del.), 713

Z**ZETIA**

Anticholesterol drug patent (D.N.J.), 553; settlement,
622
Generic, 603

ZOCOR

Cholesterol drug and rhabdomyolysis, 400

ZOMETA

Bone drug infringement suit (D. Del.), 982

ZSP-6

Fibromyalgia drug, FDA panel rejection, 1117

ZYCLARA

Actinic keratose treatment approval, 431

ZYFLO CR

Asthma drug ads, FDA letter, 899

ZYMAR

Conjunctivitis patent invalid (D. Del.), 851

ZYPREXA

Antipsychotic off-label use settlement (E.D.N.Y.), 488

Diabetes suit, no summary judgment (E.D.N.Y.), 62

Discovery documents, release barred (2nd Cir.), 1145

Learned intermediary (2nd Cir.), 948

Overpayments class decertified (2nd Cir.), 1217

Time-barred suit (E.D.N.Y.), 184

Trademark, counterfeiting conviction vacated (5th Cir.), 320

Unapproved uses, Miss. settlement (Miss. Cir. Ct.),
204

Validity of patent, rehearing ordered (Fed. Cir.), 1036